Modelling medulloblastoma pathogenesis and treatment in human cerebellar organoids.

Thomas Willott[1*], James G Nicholson[1*], Yunchen Xiao[1], Olumide Ogunbiyi[2], Benjamin Draper[3], Talisa Mistry[2], Laura Donovan[3], Nicolae Radu Zabet[1], Ashirwad Merve[2], Sara Badodi[1+] & Silvia Marino[1,4+]

[1] Brain Tumour Research Centre, Blizard Institute, Queen Mary University of London, London (UK)

[2] Department of Histopathology, Great Ormond Street Hospital for Children NHS Foundation Trust, Great Ormond Street, London (UK)

[3] UCL Great Ormond Street Institute of Child Health, London (UK)

[4] Barts Brain Tumour Centre, Queen Mary University of London and Barts Health, London (UK)

*shared first authors

[+]shared senior authors: s.badodi@qmul.ac.uk and s.marino@qmul.ac.uk

Abstract

Faithful genetically engineered *in vivo* models of medulloblastoma (MB) are currently available only for some molecular subgroups, in keeping with recent studies showing the unique role of human-specific progenitors in the development of G3 and G4 MB subgroups. We generated human cerebellar organoids (CbO) from expanded potential stem cells (EPSC) and characterised their epigenetic and transcriptomic profile compared to the developing human cerebellum. We show the presence of sub compartment-specific cerebellar lineages linked to MB formation, including populations expressing signature genes of putative G3 and G4 MB cells-of-origin. We show that these lineages can be genetically engineered to model MB tumour onset. Moreover, we demonstrate that CbO sustain proliferation and invasion of G3/4 MB cells in a 3D co-culture model (CbO-MB) while preserving their molecular identity, and that treatment of CbO-MB with anti-tumour compounds recapitulate the efficacy of *in vivo* drug testing in xenograft models.

Introduction

Medulloblastoma (MB) is a cerebellar tumour accounting for the largest proportion of brain cancer diagnoses in children. Molecular subgrouping based on transcriptomic, epigenomic and genomic features has collectively identified 4 MB subgroups: SHH (Sonic Hedgehog), WNT (Wingless-related Integration Site), Group 3 (G3) and Group 4 (G4), each further divided into subtypes with distinct prognosis and responses to therapy[1-4]. Despite these advances in classification, MB standard of care remains unchanged, with patients undergoing surgical resection followed by chemotherapy and/or radiotherapy[5], which, albeit effective in a majority of patients, is associated with significant side effects.

The origins and molecular alterations for SHH and WNT MB are well characterised, leading to a surge in the development of molecularly targeted and/or immunotherapies in *in vitro* and *in vivo* models translating into early-phase clinical trials for patients in recent years[6]. The unclear origin and lack of universal pathway aberrations in G3/G4 MB subgroups along with the consequent lack of faithful pre-clinical models has hampered the identification of new treatment options for these tumours[7]. In particular, *in vitro* models for G4 MB, the most common MB subgroup, are highly underrepresented compared to other subgroups due to difficulties establishing 2D cell culture, whilst currently available G3 MB cell lines predominantly harbour *MYC* amplifications without encompassing the heterogeneity seen in these tumours[8,9]. The maintenance of primary MB cells as patient-derived orthotopic xenograft (PDX) models has overcome some of these issues[10-12], however, the cost and resources required for these models limit their broader applications and scalability for drug testing.

MB formation is closely linked to deregulated cerebellar development[13]. Mapping lineage trajectories from MB single cell RNA sequencing (scRNA-Seq) data to human foetal cerebellar development has recently identified spatiotemporally restricted mitotic glutamatergic neuron progenitors in the rhombic lip subventricular zone (RL^{SVZ}) harbouring photoreceptor (PRC) and unipolar brush cell (UBC) gene signatures as putative G3 and G4 MB cells of origin respectively[14,15]. These progenitors are halted in development prior to cell cycle exit leading to malignancy. Importantly, immunohistochemical and pseudo-time comparisons of relevant stages of human and murine cerebellar development showed significantly fewer of these proliferative

progenitors in mice, raising the possibility that mouse models may not allow the study of key features of G3/G4 MB, including their onset[14,15]. Additionally, a human-specific transitional cell progenitor (TCP) population has been identified in the developing foetal cerebellum at 12-14 PCW, which is maintained or enriched in G3/4 MB tumours[16]. More recently, neural stem cells in the RL^{VZ} harbouring a *PRTG*$^{+}$;*SOX2*$^{+}$;*MYC*^{high};*NESTIN*^{low} signature have been linked to G3 MB onset[17]. These studies suggest that the failed maturation of early cerebellar cell lineages at specific sub-compartment location and developmental stage is linked to the ontogeny of G3/4 MB tumours.

Advances in organoid research have enabled the generation of new tools to study various aspects of cancer biology, including tumour initiation[18], metastasis[19] and as a co-culture model for drug testing[20], with important implications for personalised medicine[21]. Methods to generate cerebellar organoids from induced pluripotent stem cells (iPSC) have been developed[22,23] and characterised at single cell transcriptome level, achieving neuronal and glial differentiation with cerebellar sub-compartment identity[24-26]. In the context of MB modelling, current applications of cerebellar organoids are restricted to studies of neoplastic transformation in bulk genetically engineered organoids which lacked specificity for their respective cell-of-origin[27,28], or in co-culture with established MB cell lines belonging to the SHH subgroup[29].

Here, we have generated human cerebellar organoids (CbOs) from expanded potential stem cells (EPSC) and assessed their suitability to model G3/G4 MB. We have shown that they contain the putative MB cell-of-origin at stages of differentiation comparable to foetal cerebellar development and demonstrated that these cells can be genetically engineered to model early events in tumour initiation. In addition, we have analysed the suitability of CbOs as a co-culture model of G3/G4 MB providing insight into MB transcriptional state heterogeneity and tumour-microenvironment interactions. Finally, we show the value of the model as a pre-clinical drug testing tool.

Results

CbO display a cellular composition recapitulating human cerebellar development.

We generated human CbO from two EPSC lines (CbO19 and CbO61) obtained from reprogramming of dura mater fibroblasts and extensively previously characterised[21,30]. Organoid differentiation was followed for 35 days, as outlined in previously published iPSC-derived protocols (Figure 1A and S1A)[22,23]. We observed a significant increase in organoid size throughout differentiation (Figure S1B) and the formation of characteristic flat-oval neural rosettes at Day 35 (D35) of culture (Figure 1B). Expression of the stemness marker *NANOG* showed a significant decrease by D7, confirming the commitment of the EPSC to differentiate (Figure S1C). Additionally, the neural stem cell (NSC) markers *NESTIN* and *SOX1* demonstrated early expression from D7-14, as well as the cerebellar homeobox and developmental genes *EN2* and *OTX2,* involved in early isthmic organiser signalling[62] (Figure 1C and Figure S1D). Early progenitor markers *KIRREL2* and *PAX6* were expressed at D7-14 followed by markers of more mature precursors including *OLIG2/SKOR2* and *ATOH1/BARHL1* at D21-28, indicating the presence of GABAergic and glutamatergic lineages respectively (Figure 1C and Figure S1E, F). Interestingly, the transcription factor *EOMES,* expressed in glutamatergic progenitors and later in UBC, was expressed both in early (D7) and late (D28-35) stages of CbO maturation (Figure 1C and Figure S1F). The presence of GABAergic and glutamatergic granule neurons (GN) was confirmed by expression of CALBINDIN and Neu-N proteins respectively, proximal to SOX2-positive neural rosettes at D35 (Figure 1D and 1E). We observed similar patterns of expression throughout the differentiation of CbO19 and CbO61 (Figure 1C), in keeping with the conclusion that these CbOs reproducibly differentiate into cerebellar cell lineages.

To characterise in depth the cellular composition of CbO we performed scRNA-seq at D7, D35 and D49 timepoints to capture the earliest and more mature stages of cerebellar development and neurogenesis (Figure 1F). Initial data exploration revealed broad differences between D7 and the more heterogeneous D35 and D49 timepoints which were separated for downstream analysis (Fig S1G). Louvain clustering and Uniform Manifold Approximation and projections (UMAP) of D7 CbO cells identified three broad clusters corresponding to *PAX6*$^{+}$ and *OTX2*$^{+}$ glutamatergic progenitors, *PAX2*$^{+}$, *PAX5*$^{+}$ and *PKDCC*$^{+}$ GABAergic progenitors and SOX9^{+} and S100B^{+} glial progenitors. We further identified a small population of nascent

128 *NEUROD4*⁺ and *NEUROG1*⁺ glutamatergic neurons, suggesting an initial lineage
129 commitment (Figure S1H and S1I). By D35 and D49 there was a greater degree of
130 cellular diversity, and we identified 17 clusters (Figure S1J), with none specific to either
131 timepoint (Figure S1K). Clusters were annotated based on their expression of marker
132 genes (Figure 1G, H) and correlations to endogenous cell types from reference
133 datasets of human developing cerebellum (Figure S1L)[16,42-44]. We identified non-
134 committed *MKI67*⁺ and *CCN1B*⁺ cycling progenitors as well as *OTX2*⁺ and *SOX2*⁺
135 progenitor clusters. Two NSC clusters were identified, a broad cluster of *SOX1*⁺,
136 *SOX2*⁺, *EN2*⁺ and *NES*⁺ NSCs and a more defined cluster expressing *SOX2*⁺, *PRTG*⁺
137 and *PAX6*⁺. We found several clusters associated with glutamatergic lineages
138 including two clusters of *BARHL1*⁺ and *RBFOX3*⁺ progenitors characterised by *PAX6*
139 or *ATOH1* expression (glut_progenitors and GN/UBC_progs respectively).
140 Additionally, we detected a *NEUROD1*⁺ GN/UBC cluster also expressing mature
141 glutamatergic neuronal markers (*LMO1* and *GABRA2*) and a *NEUROD6*⁺ and *MEIS2*⁺
142 glutamatergic progenitor cell (GPC) cluster. We further identified two mixed clusters
143 of maturing cerebellar neurons (matCN1 and matCN2) positive for *MEIS2, SLC17A6*
144 and *NR4A2* which are expressed by neurons located in the neural transitory zone
145 (NTZ) during cerebellar development[44]. We further observed a neuronal cluster of
146 GABAergic *SKOR2*⁺, *LHX1*⁺ and *GAD2*⁺ Purkinje cells as well as *FABP7*⁺ and
147 *SLC1A3*⁺ Bergmann glial cells (Berg_Glia). In addition to cerebellar lineages, we also
148 identified other hindbrain clusters containing cell types contributing to cerebellar
149 development, including *FOLR1*⁺ and *RSPH1*⁺ ependymal/choroid plexus, *POST*⁺ and
150 *COL1A1*⁺ meninges and *SLIT2*⁺ and *RSPO3*⁺ roof plate (Figure 1G, H).

151 Our data show that the cellular composition of CbO recapitulates the main cell types
152 found during cerebellar development.

153

154 **Maturation of CbO follows conserved epigenetically-regulated central nervous**
155 **system developmental pathways.**

156 Epigenetic regulation of gene expression, in particular DNA methylation, plays a
157 fundamental role during central nervous system (CNS) development as it controls the
158 spatio-temporal activity of cell lineage-specific genes[63]. Hence, we analysed the DNA
159 methylation profile of CbOs during differentiation and maturation (Figure 2A). We
160 identified genes showing the most variable time-dependent methylation status (VMGs)

during CbO development and grouped them into time-dependent methylation programs by k-means clustering. Among genes exhibiting an increasing methylation status during CbO maturation (clusters 1 and 2) we found transcription factors linked to early cerebellum development including *PAX2*, *PAX5* and *PAX6* and to cell lineage specification such as *LMX1A* and *OTX2*. On the contrary, genes involved in neuronal differentiation and axon-guidance including *MAP2*, *MAP4*, *MAP7* and *GRIP1* were progressively hypomethylated during CbO differentiation (cluster 4 and 5) (Figure 2B). Gene Ontology (GO) pathway analysis of the identified VMGs revealed that early hypomethylated clusters were enriched for biological processes related to embryogenesis, fate specification, and organ development. Conversely, genes displaying later hypomethylation patterns were associated with neuronal differentiation, signal transduction, and structural functions such as synaptic junctions and neuron projections (Figure 2C). Analysis of human cerebellar samples (Figure S2A) revealed similar clustering of VMGs with distinct methylation patterns through human development (Figure S2B). GO analysis of human VMG clusters demonstrated shared earlier pathways with CbOs including those involved in proliferation and tissue development, followed by later pathways associated with signal transduction, neuron projection and catalytic activity (Figure S2C). Notably, we identified 1086 common VMGs demonstrating similar changes in methylation status between human and CbO samples (Figure 2D) suggesting that CbOs recapitulate epigenetic regulation of the human foetal cerebellum. Finally, we integrated DNA methylation and RNA expression analysis to identify genes with concordant methylation status and expression between D7 and D35 (i.e. hypomethylated and upregulated or hypermethylated and downregulated, Figure 2E). We found a significant enrichment for pathways involved in tissue morphogenesis, proliferation and receptor signalling for hypermethylated/downregulated genes expressed during early CbO development and enrichment of neuronal synapse pathways for hypomethylated/upregulated genes expressed later in CbO differentiation (Figure S2D).

Taken together, our data show that maturation of CbOs is governed by epigenetic regulation of key developmental pathways similar to the human cerebellum.

CbOs reproduce the spatiotemporal cellular complexity required for medulloblastoma initiation.

194 Next, we compared DNA methylation profiles of CbO and human foetal cerebellum
195 samples to stage the development achieved. We observed the highest correlation of
196 D35 CbO with 12-17 PCW cerebellum by comparing the methylation profiles of the top
197 1% of CpG probes with a linear correlation of methylation status across human foetal
198 cerebellar development (Figure 3A and Figure S3A). Similarly, the application of an
199 epigenetic clock algorithm trained on independent foetal brain datasets[57] showed a
200 positive correlation between differentiation of CbO and their predicted epigenetic age
201 (R-squared = 0.8), confirming the staging of D35 CbO at 14 PCW and progressive
202 maturation of the organoid (Figure S3B).
203 Moreover, we analysed pseudo-bulk CbO RNA-seq data against the average
204 expression of reference datasets[16,42-44] from developing cerebellum and observed that
205 D35 CbO show a high correlation in expression of age-related genes with 9-15 PCW
206 (Figure 3B). Interestingly, our D35/49 CbOs acquire a similar expression profile to
207 other cerebellar organoids cultured for longer time periods[24,25,43] (Figure 3B).
208 Putative G3/4 MB cells-of-origin were first described in the RL^{SVZ}, and we indeed saw
209 an enrichment of an RL^{SVZ} gene signature score in the glutamatergic cerebellar
210 neuronal and progenitor clusters, which was depleted in less differentiated cycling
211 progenitors and NSC (Figure 3C). Correlation of CbO methylation levels to
212 microdissected RL and EGL samples[14] revealed an increased correlation through CbO
213 development with both regions, reflecting the expanding populations of predominantly
214 glutamatergic neuronal progenitors in the CbO, and showing high correlation of D35
215 CbO specifically with RL (Figure 3D)..
216 Previous studies showed enrichment of photoreceptor and UBC expression signatures
217 in RL^{SVZ} ($PRC.RL^{SVZ}$ or $UBC.RL^{SVZ}$), with a high expression in G3 and G4 MB putative
218 cells-of-origin respectively. Quantification of these signatures within CbOs confirmed
219 their enrichment in discrete clusters of glut_progenitors or GN/UBC_progs
220 respectively, with the $UBC.RL^{SVZ}$-enriched GN/UBC_prog cluster also highly
221 correlated to TCP cells (Figure S1L), a progenitor population previously associated
222 with G3/4 MB[16]. Importantly, both of these progenitor clusters were characterised by
223 *EOMES* expression (Figure 3E, F and Figure S3C) and we observed $EOMES^{+}Ki67^{+}$
224 cells located predominantly within the neural rosettes in CbO, reminiscent of the
225 human-specific G3 and G4 MB-susceptible progenitors (Figure 3G, H).
226 Notably, the early_RL/NSC cluster, which RNA velocity analysis predicts to give rise
227 to $PRC.RL^{SVZ}$-enriched glut_progenitors, presents high expression of *PRTG, SOX2*
228 and *MYC* and low expression of *NESTIN* (Figure 1H, S3D), mirroring the gene

229 signature found in a *PRTG*$^{+}$;*SOX2*$^{+}$;*MYC*^{high};*NESTIN*^{low} stem cell population in the
230 RL^{VZ} recently proposed as a putative G3 cells-of-origin[17]. Immunohistochemical
231 staining revealed PRTG^{High};SOX2^{+} cells outside of CbO neural rosettes in areas
232 presenting concomitant low expression of NESTIN (Figure 3I, J), suggesting a spatial
233 complexity to glutamatergic NSC/progenitor cells in CbOs with differing MB cell-of-
234 origin signatures.

235 Given that pre-malignant G3/4 MB cells-of-origin are thought to persist in the RL, likely
236 due to their stalled differentiation[15], we performed pseudotime and RNA velocity
237 analysis through the D35/49 UMAP (Figure S3D,E). Plotting G3 and G4 trajectories
238 through each UMAP demonstrated sequential expression of glutamatergic neuronal
239 genes associated with early lineage commitment, progenitor expansion and more
240 mature neurons (Figure S3F). We observed an earlier high expression of the G3-
241 associated genes *PRTG, OTX2* and *MYC* during sustained *SOX2* expression in the
242 G3 trajectory in line with G3 cells-of-origin harbouring stem and early progenitor
243 phenotypes (Figure 3K). Whereas, in the G4 trajectory, MB-associated genes *EOMES*
244 and *PAX6* exhibited high expression relatively later in pseudotime, after *SOX2* loss
245 and before upregulation of the mature glutamatergic marker *SLC17A6*, highlighting a
246 more committed progenitor cell population (Figure 3K).

247 Taken together, our data show that D35 CbOs display an epigenetic and
248 transcriptional landscape mirroring the cerebellar developmental stage and cellular
249 profiles of G3/G4 MB initiation.

250

251 **Genetic editing of MB cell-of-origin populations in CbO models tumour onset.**

252 Leveraging the observation that CbO mirrors the cellular complexity of the human
253 cerebellum at the time of G3/G4 MB formation, we sought to model tumour initiation
254 in CbOs by specifically targeting their relevant cell-of-origin.

255 We set out to overexpress the GFP-tagged *c-MYC* oncogene in G3/G4 progenitors
256 and to achieve selective spatio-temporal targeting of the cells we used a Tet-inducible
257 system driven by the promoter of *PAX6* or *EOMES*, transcription factors known to have
258 a role in MB[64,65] and expressed in MB cell-of-origin clusters at D35 of CbO
259 differentiation (Figure 1H, S3C, 3K). EPSCs transduced with either *pEOMES;MYC-*
260 *GFP* or *pPAX6;MYC-GFP* were used to generate CbOs and c-*MYC* overexpression

261 was induced at D35 of maturation (Figure 4A). A *BFP* tag was added to p*EOMES* and
262 p*PAX6* constructs to allow purification of the engineered cells from non-induced CbOs
263 and we confirmed retention of early stem cell markers expression in transduced EPSC
264 (Figure S4A). Foci of c-MYC-GFP^{+} cells were observed as early as 4 days after
265 doxycycline treatment in both editing systems, with their expansion observed upon
266 maturation (Figure S4B). D63 CbO showed clusters of highly proliferative GFP^{+}Ki67^{+}
267 cells, which corresponded to areas of densely packed hyperchromatic and mitotically
268 active cells (Figure 4B).

269 To investigate the transcriptional consequences of *c-MYC* activation in the putative
270 G3/4 cells-of-origin, we next performed scRNAseq on edited CbOs, transferring cell
271 type labels from our previously annotated D35/49 dataset. c-*MYC* expression was
272 particularly high in a cluster made up almost exclusively of cells from *pEOMES;MYC-*
273 *GFP* and *pPAX6;MYC-GFP* CbO samples (cluster 12) that we therefore labelled as
274 *MYC* overexpressing (MYC^{OE}) cluster (Figure 4C, D and Figure S4C, D). Gene
275 signature scoring confirmed the proliferative status of the MYC^{OE} cluster as well as its
276 similarity to G3 MB[47] (Figure S4E, F). Gene set enrichment analysis of the MYC^{OE}
277 cluster confirmed enrichment of downstream MYC targets (Figure S4G) and GO
278 enrichment of upregulated cluster markers highlighted terms consistent with
279 epigenetic dysregulation (protein-DNA complex disassembly, chromatin remodelling,
280 regulation of DNA methylation) and signalling pathways linked to MB (Notch signalling
281 pathway, inositol phosphate-mediated signalling) (Figure 4E)[35,66]. Interestingly, we
282 found enrichment of oncogene-induced senescence, a result in apparent contrast with
283 the relatively proliferative signature scoring for this cluster but likely reflective of the
284 countervailing forces of tumour suppression and oncogenic signalling as these cells
285 undergo transformation.

286 Transformation of MB cells-of-origin has been linked to their stalled differentiation[15],
287 we therefore projected MYC^{OE} cells onto the D39/45 CbO UMAP (Fig 4F). As
288 expected, the MYC^{OE} cluster from *pEOMES;MYC-GFP* CbO samples (p*EOMES*-
289 MYC^{OE}) overlaid the G4 lineage whereas those from the *pPAX6;MYC-GFP* CbOs
290 (p*PAX6*- MYC^{OE}) were more equally distributed between the G4 and G3 lineages.
291 Notably, G4 lineage and p*EOMES*- MYC^{OE} cells express *ATOH1*, while the G3 lineage
292 and p*PAX6*- MYC^{OE} express higher levels of *PRTG* and *OTX2* (Fig 4G), supporting
293 our choice of *PAX6*/*EOMES* promoters to target specific progenitor clusters.

294 We next scored cells for patient-derived MB gene signatures, confirming that both our
295 G3/4 lineage and MYC^{OE} clusters were more similar to G3/4 subgroup (Figure 4H).
296 Importantly, we observed a significantly higher G3/4 MB signature score (Figure 4I) in
297 engineered MYC^{OE} cells compared to their G3/4 lineage cells-of-origin alongside with
298 significant depletion of gene sets associated with neuronal differentiation and
299 enrichment of a gene set corresponding to poor MB prognosis (Figure 4J and S4H).

300 We further investigated the methylation profiles of sorted GFP^{+}-MYC^{OE} cells as
301 compared to BFP^{+} lineage-of-origin controls and found that they clustered with G3 MB
302 patient tumours, as assessed by a MB subgroup-specific CpG probe set[1,59] (Figure
303 S4I). Furthermore, when focusing the analysis on DMPs between MYC^{OE} and lineage-
304 of-origin we observed a stronger correlation to G3 MBs for the *pPAX6*-MYC^{OE}
305 compared to *pEOMES*-MYC^{OE} model (Figure S4J). Interestingly, analysis of DMGs
306 revealed model-specific deregulation of genes with *pPAX6*-MYC^{OE} demonstrating
307 specific hypomethylation of *OTX2* and *GFI1*, known drivers of G3 MB onset[27], whilst
308 *pEOMES*-MYC^{OE} showed hypomethylation of genes with mutually exclusive roles to
309 *OTX2* in G3/4 MB pathogenesis and cell fate decisions including *PAX3* and
310 *CBFA2T2*[15,64] (Figure 4K). Integration of DNA methylation and gene expression data
311 further showed a concordant positive regulation of several key genes (*HMGA1*,
312 *SLC7A5* and *FABP3*) and negative regulation of genes associated with neuronal
313 differentiation (*SALL2*, *NEUROD2* and *GRIA2*) (Figure 4L).

314 Taken together, we show that using CbO we can model features of MB onset in G3/4
315 lineages-of-origin through *c-MYC* overexpression including increased proliferation,
316 stalled development and transcriptional changes consistent with epigenetic
317 dysregulation and poor MB outcome.

318

319 **CbOs sustain co-cultured medulloblastoma cells proliferation and invasion**
320 **while preserving their molecular identity.**

321 As well as utilising CbO to model early events in MB cell-of-origin transformation, we
322 also set out to assess whether CbO could provide a physiologically relevant 3D
323 environment for sustaining growth of human MB cells. We co-cultured GFP-tagged
324 G3/4 MB cell lines (CHLA-01-Med, CHLA-01R-Med and ICb1299) as well as G3 MB
325 primary cells (Med211-FH) maintained as a PDX with D35 CbO when cerebellar
326 lineages are clearly defined (Figure 5A). All MB lines successfully attached and

327 infiltrated the CbO with considerable cell growth after 14 days of co-culture (Figure 5A
328 and S5A-C). Morphological analysis of CbO bearing MB cells (CbO-MB) showed a
329 highly cellular and proliferative pleomorphic embryonic tumour, in keeping with MB,
330 diffusely infiltrating the adjacent CbO tissue (Figure S5D-F). We observed positivity
331 for the proliferation marker Ki67 in around 30% of GFP^+ MB cells (Figure 5B), thus
332 confirming that CbOs can sustain MB cells proliferation and infiltration.

333 To explore the effect of MB cells on CbO, we performed scRNA-Seq on pooled CbO-
334 MB samples (CHLA-01-Med or Med211-FH) after 14 days of co-culture (Figure 5A),
335 as well as control CbOs co-cultured with cerebellar NSCs (NSC73.5, CbO-NSC).
336 Louvain clustering and inferred copy number analysis identified CHLA-01-Med and
337 Med211-FH MB cells (Fig 5C, S5G-H) expressing tumour-specific markers
338 (*SIX3*/*APOE* and *NEUROD1*/*BCAT1* respectively) as well as shared MB-specific
339 markers we previously observed in our modelled MYC^{OE} cells (*HMGA1*, *MYC*, *YBX3*
340 and *TRAP1*). NSC73.5 cells could be distinguished by their separation in the UMAP,
341 and expression of stemness markers (*SOX2/9*), doublecortin (*DCX*) and transcription
342 factors governing interneuron development (*DLX1/2*) (Figure S5I). In keeping with the
343 highly proliferative properties of tumour cells, we identified MB cells representing more
344 than 80% of the sequenced CbO-MB cells as compared to NSC73.5 forming around
345 20% of CbO-NSC (Figure 5C).

346 To investigate the degree to which co-cultured CbO-MB cells retain their subtype
347 specificity, we computationally isolated co-cultured MB cells and scored them for
348 patient-derived MB gene signatures[45]. We observed a significant increase in average
349 G3/G4 metaprogram scores when compared to WNT or SHH scores (Figure 5D),
350 indicating that both MB cell lines retained their molecular subtype in the CbO-MB
351 model. We next correlated pseudobulk transcriptional profiles with the same reference
352 cohort of patient MB tumours[45]. As expected, CHLA-01-Med fell within an intermediate
353 subcluster containing both G3 and G4 primary tumours, whilst Med211-FH clustered
354 with G3 tumours only (Figure 5E). Label transfer of G3 and G4 tumour scRNA-seq
355 profiles onto co-cultured MB clusters further confirmed these subgroup identities
356 (Figure S5J). Studies of glioblastoma have shown that tumour cells more closely
357 recapitulate their parental tumours when co-cultured in brain organoids as compared
358 to 2D models[21]. We therefore correlated expression profiles of each MB line co-
359 cultured with CbO or in 2D with patient tumour samples[35,45]. Importantly, we observed
360 a significantly higher correlation in all co-cultured MB cells compared to their 2D

361 cultured counterparts (Figure 5F), suggesting that CbO-MB better phenocopy *in vivo*
362 primary tumours.

363 These data show that CbO represents a novel 3D model for G3 and G4 MB cell growth
364 and expansion which is superior at preserving features of patients' tumour samples as
365 compared to 2D cultures.

366

367 **Group 3 MB cells harbour a subset of cells with myogenic differentiation**

368 We next analysed the MB fraction of CbO-MB co-cultures, performing Louvain
369 clustering and correlating cluster marker signature to each other and to references of
370 the developing cerebellum (Figure 6A-C and Figure S5K). In line with previous studies,
371 both cell lines were predominantly composed of clusters corresponding to cycling and
372 non-cycling GCP-like cells (clusters 1,7, and 2 for Med211-FH; clusters 3 and 0 for
373 CHLA-01-Med). Overall, Med211-FH clusters correlated more closely with developing
374 cerebellar cell types than those from the CHLA-01-Med cell line and expressed genes
375 consistent with a more neural phenotype (*SYT1, NEUROD1*). We also identified two
376 pairs of smaller cell states that were common to both MB lines, clusters 8 and 5 and
377 clusters 4 and 6 from Med211-FH and CHLA-01-Med, respectively (Figure 6D).
378 Clusters 8 and 5 correlated to glial progenitor/NSC developing cerebellar cell types
379 (Figure S5K) and specifically expressed stemness markers (*SOX2*, *NTRK2*) (Figure
380 6C). GO enrichment of the 44 shared marker genes highlighted terms associated with
381 neuronal development and radial glia differentiation (Figure 6E). Clusters 6 and 4
382 showed a phenotype more consistent with immune reference cells and expressing
383 immune-associated markers such as *IL17B* (Figure 6C and Figure S5K). Further
384 analysis of the 127 shared marker genes between clusters 6 and 4 revealed a strong
385 enrichment of GO terms associated with myogenic development and differentiation
386 (Figure 6F). This included expression of key transcription factors governing myogenic
387 differentiation (*MYOG, MYOD1* and *HLHL41*) as well as components of the myosin
388 light chain (*MYL4*) and troponins (*TNNT1*) (Figure 6C) with MYOGENIN^{+} MB cells
389 confirmed by IHC in CbO-MB co-cultures (Figure 6G). Previous histological studies
390 have reported aberrant myogenic differentiation of MB cells[67,68], but the transcriptional
391 state associated with such phenotypes has not previously been described. By scoring
392 reference MB samples[45] for our CbO-MB derived myogenic state signature, we
393 observed the highest score in the WNT MB subtype (Figure 6H) while analysis of

394 Group 3 MB revealed a subset of cells scored highly for our signature suggesting
395 heterogenous expression of this metaprogramme (Figure 6H). Indeed, upon sub-
396 setting, and re-clustering Group 3 MB samples we observed two clusters, 4 and 6,
397 which expressed this myogenic signature strongly (Figure 6I). These myogenic cells
398 were found in 11/16 samples ranging from 0.3-70% of total cells (Figure 6J). Scoring
399 of the myogenic signature in a larger cohort of 763 MB samples[1] revealed a similar
400 distribution across MB groups (Figure 6K), with an enrichment in the poor prognosis
401 MYC-amplified Group3_gamma subtype (Figure 6L) and a significant reduction of
402 survival in samples scoring highly (> median) for the myogenic signature (Figure 6M).

403 Overall, we identify a subset of MB cells in CbO-MB exhibiting myogenic differentiation
404 which is recapitulated in patient tumours and linked to poorer prognosis.

405

406 **CbO-MB co-cultures reveal a differential impact of medulloblastoma**
407 **engraftment on cells of the tumour microenvironment.**

408 Little is known about the MB tumour microenvironment (TME), both in terms of the
409 crosstalk between MB cells and non-neoplastic neuronal lineages and the molecular
410 regulators of this interaction, or about the contribution of the MB-TME interplay to
411 treatment response and recurrence in patients[69]. To investigate how MB cells affect
412 CbO cellular complexity, we identified CbO-specific cell types in CbO-MB, annotating
413 clusters based on label transfer using our non-co-cultured organoid as reference
414 (Figure 7A and Figure S6A-C). The most striking difference was a depletion of mature
415 cerebellar neurons (MatCN) which was evident in all CbO-MB co-cultures but absent
416 in the CbO-NSC co-culture control (Figure 7B and Figure S6C,D). Selective negative
417 impacts on neuronal populations have been shown in other brain tumour organoid co-
418 cultures[70,71], we therefore reasoned that MB co-culture was most likely causing
419 neuronal death. Using IHC, we validated the presence of apoptotic neurons (cCASP3^{+}
420 and MAP2^{+}/TubIII^{+}) proximal to GFP^{+} MB cells which were not present in CbO-NSC
421 controls (Figure 7C and Figure S6E).

422 To characterise the molecular events mediating MB-TME crosstalk we modelled
423 receptor-ligand (R/L) interactions in CbO co-cultures using CellphoneDB. Overall, we
424 found that both CHLA-01-Mef and Med211-FH cells had fewer R/L interactions with
425 CbO cells than NSC73.5 controls (Figure S6F), in keeping with MBs demonstrating
426 limited TME reactivity compared to other brain tumours [69]. Among the 27 cancer-

427 specific R/L interactions shared between MB cells but absent in NSC73.5 (Figure 7D),
428 we observed interactions mediated by the cell adhesion protein CADM3, the NOTCH
429 signalling pathway, the receptor NRP2 as well as glutamate signalling via SLC1A7
430 and SLC17A7 (Figure 7E). We validated the predicted NOTCH1/DLL3 interaction
431 between MB and cycling progenitor clusters using immunohistochemistry, revealing
432 NOTCH1^{+}SOX2^{+} CbO cells proximal to GFP^{+} MB cells, as well as co-localisation of
433 NOTCH1 and DLL3 specifically on MB cells surface (Figure 7F).

434 To gain further insights into the effect of MB cells on the surrounding CNS tissue, we
435 investigated cell type-specific transcriptional modulation caused by the presence of
436 MB cells and identified differentially expressed genes (DEGs) (Figure S6G). GO
437 analysis showed a downregulation of synapse and cytoskeletal pathways in GPCs
438 whilst Ependymal/ChP cells demonstrated downregulation of cilia-related pathways
439 and cholesterol metabolism, suggesting changes to the normal development of these
440 populations within CbO-MB (Figure S6H). Altered neurogenesis, development and
441 apoptosis pathways in stem/progenitor populations further highlight negative changes
442 elicited by MB on CbO populations, suggesting a more stressed cell state.
443 Interestingly, meningeal cells exhibited a downregulation in apoptosis and
444 upregulation in metabolic pathways, perhaps indicating these cells better tolerate the
445 tumour burden in CbO-MB co-cultures (Figure S6H).

446 Our data show that CbO-MB is a 3D model suitable for studying cell-cell interactions
447 and molecular events/cascades induced by MB cell engraftment and identifies specific
448 populations of CNS tissue that are more exposed to detrimental stimuli during MB
449 formation and expansion.

450

451 **CbO-MB are an effective pre-clinical drug testing tool.**

452 Following on from the observations that CbO-MB maintain tumour cells in a molecular
453 state closer to human samples whilst simultaneously providing insights into the
454 functional impact of MB growth on the surrounding cerebellum, we sought to
455 investigate whether CbO-MB could be suitable as a drug testing tool. We previously
456 demonstrated that combination therapies extend the survival of mice xenografted with
457 MB cells recapitulating a specific molecular signature found in a proportion of MB
458 tumours, whereby the polycomb group gene BMI1 and the chromatin remodelling
459 factor CHD7 are overexpressed and downregulated, respectively (BMI1^{High};CHD7^{Low}).

460 Treatment with BMI1 (PTC-209) and MAPK (PD325901) inhibitors demonstrated a
461 synergistic, cytotoxic effect on BMI1^{High};CHD7^{Low} MB cells whilst the phospho-inositol
462 metabolic modulator IP6 exerted cytostatic anti-tumour efficacy[35,72]. Here, we co-
463 cultured GFP-tagged BMI1^{High};CHD7^{Low} CHLA-01-Med cells with D35 CbO and treated
464 CbO-MB at 14 days, a timepoint when a large population of proliferative MB cells was
465 established (Figure 5A, B), with BMI1/MAPK inhibitors or IP6 for four days (Figure 7G).
466 We observed a significant decrease of GFP^{+} BMI1^{High};CHD7^{Low} MB cells upon both
467 treatments and concomitant increase in cCASP3 or decrease in Ki67 respectively, with
468 no significant impact on CbO cells (Figure 6H-K and Figure S6I, J). This confirms that
469 MB cells grown in 3D models recapitulate the treatment response as observed in a
470 widely accepted pre-clinical *in vivo* model, whilst also indicating negligible side effects
471 on CbO-MB non-neoplastic cells.

472 Taken together, these data show that CbO-MB are an effective 3D *in vitro* drug testing
473 tool which perform similarly to *in vivo* xenograft models.

474

475 **Discussion**

476 We show that CbO faithfully recapitulate the developmental stages of the human
477 cerebellum relevant for MB initiation and contain cell lineages which display gene
478 signature enrichment for G3 and G4 MB cells-of-origin. Genetic editing of these cells
479 models MB onset and provides the first proof of concept that they play a role in MB
480 pathogenesis. Moreover, co-culture of patient-derived MB cells within the CbO
481 generates a 3D *in vitro* model which sustains MB cells proliferation and invasion while
482 preserving their molecular identity and recapitulates the results obtained in pre-clinical
483 *in vivo* drug testing.

484 Recent studies have shown the fundamental role of human-specific stem and
485 progenitor cells in the development of G3 and G4 MB[14,15,17], clearly exposing the
486 limitations of mouse models and highlighting the need for new human-specific models.
487 Putative G3 and G4 MB progenitor cells-of-origin are generated in the RL^{SVZ} upon RL
488 compartmentalisation at 11 PCW and show a specific spatiotemporal pattern that
489 peaks at around 14 PCW. Previously published cerebellar organoid protocols
490 observed a correlation between two-month-old organoid cell populations and RL cell
491 clusters from human datasets[26] and a modest enrichment for UBC.RL^{SVZ} signature in
492 the GNP cluster of a three-month-old organoid[14]. Here, we leveraged comparative

epigenetic and transcriptomic analysis of our CbO model and human cerebellar tissue samples to accurately characterise and date the development of our model and provide the first compelling evidence that it faithfully recapitulates stages of human development known to enable MB initiation. We observed a significant enrichment for RL^{SVZ} signatures in discrete cell clusters at D35 of CbO maturation stage. Importantly, we identified specific cell clusters showing enrichment for UBC.RL^{SVZ} and PRC.RL^{SVZ} expression signatures, the latter never observed before in organoid models. TCP have been reported as putative G3/4 cells-of-origin, and we found these cells to most strongly correlate to our UBC.RL^{SVZ}-high G4 MB lineage cells. Recent work suggest G3 MB originates from *PRTG*$^{+}$;*SOX2*$^{+}$;*MYC*^{high};*NESTIN*^{low} cells. We observed this less differentiated NSC population in our CbO, which immediately preceded the PRC.RL^{SVZ} -high cluster in pseudotime/RNAvelocity trajectories. Thus, our CbO data help unify these competing theories and suggest that both putative G3 cells-of-origin are partially overlapping populations corresponding to subtly different stages along a shared G3 lineage-of-origin. Interestingly, we found a difference in distribution of EOMES^{+}Ki67^{+} and PRTG^{High}SOX2^{+} cells in mature CbO with respect to neural rosettes, suggesting a spatial contribution to their differing lineage commitments mimicking the events linked to neoplastic transformation of MB cells-of-origin during human cerebellar development. Therefore, our CbO model provides an unparalleled opportunity for modelling the initiation of G3 and G4 MB by providing access to their putative human-specific cells-of-origin in a 3D experimental system.

c-MYC amplification has been robustly demonstrated as an oncogenic driver in a subset of aggressive G3 MB, as well as reported in a proportion of G4 MB[2,73]. Previous studies have overexpressed *c-MYC* in combination with other G3 drivers *OTX2* or *GFI1* in bulk cerebellar organoids, observing an increase in proliferative cells[27]. Leveraging the in-depth developmental characterisation of our CbOs, we implemented a refined MB-modelling approach, specifically overexpressing *c-MYC* oncogene in G3/4 MB lineages-of-origin in a CbO at an MB-relevant developmental stage. This spatiotemporal inducible system generated clusters of highly proliferative cells overexpressing *c-MYC* showing an increased correlation to G3/4 MB tumours at both transcription and DNA methylation levels. Strikingly, we also observed hypomethylation of *OTX2* and *GFI1* specifically in the *pPAX6* targeted G3 lineage-of-origin model, reflecting a susceptibility of specific cells in our CbO to MB transformation as seen in patients. Genetically engineered mouse models of *MYC*-

driven G3 MB derived from *in utero* electroporation of neuronal progenitors or orthotopic xenografts of cerebellar stem cells have relied on concomitant loss of *p53* function to evade cell death and induce transformation[74,75], whilst in most human G3 MB tumours *p53* remains functional[1]. We did not observe this effect in our CbO upon *c-MYC* overexpression alone, highlighting the importance of modelling the human-specific cells-of-origin at the correct stage of cerebellar maturation. Overall, we demonstrate changes in keeping with early onset MB formation upon lineage-specific disease-defining genetic editing in human CbO, paving the way for future studies leveraging this model to dissect the events involved in the progression to full blown G3 and G4 tumours.

In vitro growth of MB cells isolated from patients tissue has proven difficult, particularly for G3 and G4, thus the number of reliable MB cell lines for use in 2D *in vitro* cell culture or PDX assays is limited[8,9]. Moreover, *in vitro* expansion can lead to shifts in molecular subgrouping, an issue that is particularly relevant for G3/G4 MB[4,76]. We successfully co-cultured both established and primary G3/G4 MB cell lines with CbO, showing that our 3D co-culture model represents a valuable tool to grow and maintain primary MB cell lines for which 2D culture has proven challenging by exposing tumour cells to cell-extrinsic signals from the adjacent CNS tissue. Importantly, we observed for the first time that MB cells in the 3D CbO-MB model retain an expression profile closer to that of patient tumours as compared to 2D cultures suggesting that the CbO environment is superior in supporting and preserving the molecular identity of MB cells, as has been demonstrated in co-culture models for other brain tumours[77]. Of note, despite G3/G4 MB typically manifesting post-natally, cases of congenital MB have been reported[78,79], suggesting that the pre-natal cerebellum which we model in CbO is a permissive ecosystem for MB formation, proliferation and invasion. While multiple studies have reported the successful co-culture of primary adult glioblastoma cells with cerebral organoids[20,21] or cerebellar organoids with established MB cell lines belonging to other subgroups[29], this is the first time that this approach has been successfully applied to G3/4 or any primary MB cells.

Analysis of MB cells upon 3D co-culture identified clusters exhibiting neuronal and glial/stem-like phenotypes, as expected; however a cluster of MB cells displaying myogenic differentiation was also observed. Historically, this lineage of differentiation has been occasionally observed histologically in patients' samples[67,68], particularly in a small proportion of tumours which do not classify within the four accepted WHO

561 subgroups[80]. Scoring of patient MBs for our CbO-MB derived myogenic signature
562 revealed the highest enrichment in a subset of G3 patients, with myogenic
563 differentiation being associated with poorer prognosis. Given the fidelity with which
564 CbO-MB recapitulate this myogenic subset of G3 MB cells, they may prove a useful
565 tool to further investigate its clinical relevance.

566 The characterisation of the MB TME remains limited compared to other brain tumours,
567 with little known about the interactions or effect of MB tumours on the surrounding
568 cerebellum[69], however co-culture models have been successfully applied to identify
569 TME interactions in other primary and metastatic brain tumours[81,82]. Upon MB co-
570 culture, we observed a specific depletion of more mature neuronal CbO populations.
571 Whether this effect is directly driven by trophic signalling of co-cultured MB cells or
572 due to selection pressure within the CbO-MB linked to the highly proliferative nature
573 of MB cells remains unclear. Receptor-ligand modelling predicted SLC1A7-mediated
574 glutamate receptor signalling, which had been previously identified specifically in G3/4
575 MB tumours[83]. It also predicted interactions between MB and various CbO populations
576 via the transmembrane protein NRP2 (Neuropilin-2) which had been linked to cell
577 proliferation in an MB mouse model[84]. Proteomic studies have identified upregulation
578 of proteins involved in TGFβ specifically in the MB TME[85], whilst in our CbO-MB
579 models we also saw predicted R/L interactions associated with this pathway including
580 TGFB3/TGFBR3 and INHBE/ACVR2A[86]. We further identified and validated the
581 interaction of NOTCH1/DLL3 between MB and CbO NSC populations, previously
582 described to be involved in MB's prognosis, tumour microenvironment and
583 metastasis[87,88]. Overall, we demonstrate our CbO-MB co-culture is a useful model to
584 dissect potential TME mediators linked to MB progression and metastasis.

585 Finally, our CbO-MB model recapitulates the therapeutic response upon treatment
586 with BMI1/MAPK inhibitors and IP6 as previously demonstrated in xenograft models,
587 hence supporting its potential value as a system for testing MB subgroup specific and
588 signature-matched therapeutic approaches. Notably, CbO-MB represent a faster,
589 scalable and more cost-effective model system as compared to expansion of MB cells
590 in immunodeficient mice, whilst also offering the possibility to evaluate toxicity on
591 cerebellar cells induced by anti-tumour therapy, hence could be used in precision
592 medicine modelling to identify new treatment options that are still lacking for G3/G4
593 patients.

In conclusion, we have established a new human cerebellar organoid model which enabled access to human G3/G4 MB cells-of-origin and provided proof of concept that genetic editing of these cell lineages leads to changes defining MB onset. Moreover, CbO sustained G3/G4 MB cell growth in a co-culture system, enabling the identification of a myogenic signature linked to poor prognosis as well as modelling in 3D the tumour microenvironment. Finally, we show its potential value as a novel scalable pre-clinical screening platform for precision medicine.

602 **Material and Methods**

603 **Cell Culture**

604 Full characterisation of the two EPSC lines used in this study has been reported
605 previously[21]. Briefly, EPSC19 and EPSC61 were derived from fibroblasts isolated from
606 the healthy dura mater of two female patients harbouring no somatic mutations and
607 reprogrammed based on established protocols[30]. EPSCs were cultured as described
608 previously[21] on plates coated in Geltrex (Life Sciences) in mTEsR plus basal media
609 (StemCell Technologies). During routine passaging, cells were detached with 0.1 mM
610 EDTA (Life Sciences) and re-plated with media supplemented with 10 µM Y-27632
611 Dihydrochloride (PeproTech, #1293823). CHLA-01-Med and CHLA-01R-Med MB cell
612 lines purchased from ATCC, were cultured in suspension in Gibco DMEM-F12 media
613 (Life Technologies) supplemented with 20 ng/mL human recombinant FGF and 20
614 ng/mL human recombinant EGF (Peprotech), 2% B-27 supplement (Invitrogen) and
615 1% Penicillin-Streptomycin. ICb1299 MB cells obtained from Dr Xiao-Nan Li, Baylor
616 College of Medicine, Texas Children Cancer Centre, USA[11,31] were cultured semi-
617 adherently in Gibco DMEM media (Life Technologies) supplemented with 10% foetal
618 bovine serum (Gibco) and 1% Penicillin-Streptomycin (Life Sciences). Med211-FH
619 cells tagged with GFP were cultured in Neurobasal Plus media (Life Sciences)
620 supplemented with N2 (Bio-techne), B27 (Bio-techne), 75 µg/mL BSA, 2 µg/mL
621 heparin (StemCell Technologies), 10 ng/mL human recombinant FGF and 10 ng/mL
622 human recombinant EGF (Peprotech).
623 All cell lines were confirmed mycoplasma negative prior to experimental procedures
624 and cultured in humidified incubators at 37°C with 5% CO2 until ~80% confluent before
625 passaging.
626

627 **Cerebellar Organoid Culture**

628 Cerebellar organoids were cultured based on a previously published protocol[22,23].
629 Briefly, EPSCs at 80% confluency were detached using gentle cell dissociation
630 reagent (StemCell) and plated into 96-well ultra-low attachment V-bottomed plates
631 (PHCBI) in mTEsR plus basal media (StemCell) supplemented with 10uM Y-27632
632 Dihydrochloride (PeproTech, #1293823) at 6,000 cells per well. On Day 1, media was
633 replaced with mTEsR plus basal media. On Day 2, media was replaced with growth-
634 factor free chemically defined media (gfCDM) containing: IMDM (Life
635 Technologies)/Ham's F-12 (Life Technologies) 1:1, 1% v/v chemically defined lipid

636 concentrate (Life Technologies), 450 µM monothioglycerol (Sigma), 15 µg/ml apo-
637 transferrin (Sigma), 5 mg/ml crystallization-purified BSA (Sigma), 50 U/ml penicillin/50
638 µg/ml streptomycin and 7 µg/ml insulin (Sigma). On Day 2-7, 50 ng/ml human
639 recombinant FGF2 (PeproTech, #100-18B) and 10 µM SB431542 inhibitor (Life
640 Sciences, #S4317) were added to gfCDM. On Day 7, organoids were transferred to 6-
641 well ultra-low attachment plates (Corning) on an orbital shaker (90 rpm, Thermo
642 Scientific, #88881102) in a humidified incubator at 37°C with 5% CO2 where they were
643 maintained for the remainder of the protocol. For Day 7-14, 33.3 ng/ml human
644 recombinant FGF2 and 6.67 µM SB431542 inhibitor were added to gfCDM, then 100
645 ng/ml human recombinant FGF19 (PeproTech, #100-32) was added to gfCDM for Day
646 14-21 of culture. From Day 21, organoids were cultured in complete neurobasal media
647 containing: Neurobasal medium (Life Technologies), GlutaMax I (Life Technologies),
648 N2 supplement (Life Technologies), and 50 U/ml penicillin/50 µg/ml streptomycin. 300
649 ng/ml human recombinant SDF1 (PeproTech, #300-28A) was added to complete
650 neurobasal media from Day 28-35.
651
652 **CbO editing strategy**
653 To induce *c-MYC* expression in putative MB lineages-of-origin within developing
654 CbOs, three lentivirus constructs were designed utilising the doxycycline inducible Tet-
655 On system[32]. To target specific CbO lineages, the *rtTA* sequence element and *BFP*
656 tag were placed under the control of the *EOMES* promoter (p*EOMES*) or a *PAX6* mini
657 promoter (Ple260[33]) designed for CNS expression (p*PAX6*). In addition, each
658 construct contained the puromycin resistance gene under the control of a constitutively
659 expressed promoter (*mPGK)*, giving *pPAX6-rtTA-BFP_mPGK-PuroR* or *pEOMES-*
660 *rtTA-BFP_mPGK-PuroR*. The third construct contained the *c-MYC* sequence and *GFP*
661 tag under the control of the tetracycline responsive element (*TRE)* as well as
662 blasticidin resistance gene under the control of *mPGK,* giving *TRE-c-MYC-*
663 *GFP_mPGK-BlastR.* Lentiviral constructs were produced as described previously[34]
664 and titrated using Lenti-X GoStix Plus as per manufacturer instructions (Takara Bio).
665 EPSC19 were infected with *pPAX6-rtTA-BFP_mPGK-PuroR* or *pEOMES-rtTA-*
666 *BFP_mPGK-PuroR* (MOI = 1), negative selection for 24 hours performed with
667 puromycin (1.25 µg/mL) then co-infected with *TRE-c-MYC-GFP_mPGK-BlastR*
668 construct (MOI = 1) and Blasticidin (5 µg/mL) negative selection performed for 48
669 hours. Cerebellar organoid protocol was then begun as detailed above. From day 35,
670 doxycycline (2 µg/mL) was added to culture media and CbOs monitored for 4 weeks.

671 Two sets of controls were included, non-induced CbOs harbouring the full editing
672 system (no doxycycline control) as well as CbOs derived from EPSC infected with the
673 *pPAX6-rtTA-BFP_mPGK-PuroR* or *pEOMES-rtTA-BFP_mPGK-PuroR* constructs
674 only and treated with doxycycline from day 35 onwards (doxycycline+ control). On day
675 63, edited CbO were taken for scRNA-seq analysis, IHC (both detailed below) or
676 dissociated, FACS sorted for BFP or GFP using BD FACSAria III Cell Sorter then DNA
677 extracted and submitted for EPICv2 array (outlined below).
678

679 **CbO-MB co-culture**

680 Prior to co-culture, G3/4 MB cell lines were infected with shCHD7 lentivirus containing
681 GFP as previously published[35]. On Day 35 of CbO culture, organoids were placed in
682 96-well ultra-low attachment U-bottomed plates (Corning) in a 1:1 mix of complete MB
683 cell media and complete neurobasal media with 100,000 MB cells. For Med-211-FH
684 cells previously cultured as PDX only, cells were thawed then underwent mouse cell
685 depletion using Miltenyi mouse cell depletion kit (#130-104-694) according to
686 manufacturer instructions then seeded onto CbO as described above. The following
687 day, half media from each well was replaced with complete neurobasal media. On Day
688 37, the entire contents of each well was transferred to a 24-well ultra-low attachment
689 plate (Corning) with 1ml complete neurobasal media. On Day 4, total media was
690 replaced with complete neurobasal media to remove non-infiltrating cells and
691 organoids placed back on the orbital shaker (90 rpm) in a humidified incubator at 37°C
692 with 5% CO2. Co-cultures were maintained for 14 days in total from MB cell seeding
693 before taking for drug assays or scRNA-Seq.
694

695 **Human Cerebellar FFPE Samples Processing**

696 12 human cases from Great Ormond Street Hospital (GOSH) at pre-natal
697 developmental timepoints (19-37 post-conception weeks) were selected as having
698 normal cerebellar histology and consent for research. Areas of formalin-fixed paraffin-
699 embedded (FFPE) tissue containing cerebellar material were identified and manually
700 macro dissected according to the marking shown in Figure S2A. Following dissection,
701 tissue was kept at -20°C until downstream processing. In addition, 11 samples of fresh
702 frozen cerebellar tissue from earlier developmental timepoints (Carnegie stage 22-17
703 post-conception weeks) were obtained from the Human Developmental Biology
704 Resource (HDBR).
705

706 **DNA/RNA Extraction**

707 For cell culture samples (CbO, EPSC and Med211-FH), DNA and RNA were extracted
708 using the RNA/DNA/Protein Purification Plus kit (Norgen, #47700) following
709 manufacturer protocol. For FFPE human cerebellar samples, initial deparaffinization
710 and DNA extraction was performed using FFPE RNA/DNA Purification Plus Kit
711 (Norgen, #54300). Samples were incubated with Proteinase K overnight at 37°C to
712 increase yield, after which DNA extraction was performed as per manufacturer
713 instructions. For fresh frozen human samples, extraction was performed using
714 RNA/DNA Purification Plus Kit (Norgen, #47700) as per manufacturer instructions.

715

716 **RT-qPCR**

717 All cDNA synthesis was performed using the SuperScript III Reverse Transcriptase kit
718 (Invitrogen) according to the manufacturer's protocol. Analysis of gene expression was
719 carried out using the Applied Biosystems 7500 Real-Time PCR with SYBR Green PCR
720 MasterMix (Applied Biosystems) according to standard protocols. All qPCRs were
721 performed in triplicate with 10ng cDNA. Average Ct values for target genes were
722 normalised to average Ct of ACTIN B and GAPDH housekeeping genes before
723 calculating fold change. Primers used are listed in Table 1.

724

725 **Immunohistochemistry (IHC)**

726 Organoids were collected and fixed in 4% PFA in PBS, dehydrated in 30% sucrose in
727 PBS and embedded in blocks of 7.5% gelatin, 10% sucrose in PBS. Blocks were then
728 snap frozen in isopentane at -55°C before cryosectioning at 15 µm sections. Prior to
729 staining, sections were de-gelatinised in warm water before permeabilisation in 4%
730 normal donkey serum with 0.25% Triton-X in PBS for 2 hours. Sections were then
731 washed in PBS before incubation with primary antibodies at 4°C overnight diluted in
732 4% normal donkey serum in PBS. A list of primary antibodies and dilutions are shown
733 in Table 2. Sections were then washed 3 times in PBS followed by incubation for 3
734 hours at room temperature with corresponding AlexaFluor™ secondary antibodies at
735 1:500 dilution in PBS. After a final 3 PBS washes, sections were mounted with
736 coverslips using ProLong™ Gold antifade reagent with DAPI (Thermo Fisher
737 Scientific, P36931). Images were taken using Zeiss 800 Laser Scanning Confocal
738 microscope with Zeiss ZEN software v2.3.

739

740 **CbO-MB drug assays**

741 On Day 0 of drug assays, CbO-MB were transferred to new 24-well ultra-low
742 attachment plates (Corning) containing 500 µL complete neurobasal media plus drug
743 (PTC-209/PD325901 inhibitors or IP6) or vehicle (DMSO or PBS respectively) then
744 placed back on orbital shaker where they remained for the duration of the assay. A
745 drug and media top up was performed on day 2.
746 On day 4, the entire content of each well was collected and the Neural Dissociation kit
747 (MACS Miltenyi Biotec) was used to dissociate treated CbO-MB co-cultures into single
748 cell suspension. Samples were then stained with the Zombie NIR™ Fixable Viability
749 Kit (Biolegend) at 1:300 dilution, after which all samples were analysed using the BD
750 LSRII flow cytometer. GFP-expressing cells were detected with the blue excitation
751 laser at 488nm, while the Zombie NIR positive cells were detected with the red
752 excitation at 633nm. Upon gating of single cells, Zombie NIR positive cells were gated
753 as dead, with GFP fluorescence distinguishing viable MB from CbO cells. All
754 subsequent FACS analysis was performed in FlowJo v10.6.2.
755
756 **Dissociation of CbO and CbO-MB for scRNA-Seq**
757 Pooled samples of CbO were taken at day 7 and day 35, as well as edited CbO at day
758 63 and CbO-MB at day 49. First, organoids were dissociated using the Neural
759 dissociation kit (MACS Miltenyi Biotec) into single cell suspension. Subsequent debris
760 removal was then performed using Debris removal solution according to manufacturer
761 protocol (Miltenyi Biotec, #130-109-398) to obtain a clean sample of highly viable cells.
762 Cells were resuspended in loading buffer (0.04% BSA in PBS), strained through a 70
763 µm cell strainer and counted using a hemacytometer with trypan blue staining. At least
764 10,000 cells per sample were taken for processing using 10X Genomics kits (detailed
765 below).
766
767 **RNA sequencing**
768 Med211-FH RNA from cells cultured *in vitro* was sequenced at Novogene with paired-
769 end, 150bp sequence reads. Library preparation (mRNA, poly-A enrichment) and
770 sequencing was performed on the NovaSeq6000 platform. Reads were quality
771 trimmed using trimgalore v0.6.5 and aligned to reference genome
772 GRCh38.release109 using STAR v2.7.9a[36]. Reads were counted using featurecounts
773 function and annotated with ENSEMBL Homo_sapiens.GRCh38.109.gtf.
774
775 **scRNA-Seq Analysis**

776 Library preparation was performed at the Single Cell Genomics Facility (UCL, Cancer
777 Institute) using the Chromium Next GEM Single Cell 3' Kit v3.1 (10X Genomics,
778 1000268) along with the Chromium Next GEM Chip G Single Cell Kit (10X Genomics,
779 1000120) according to the manufacturer's instructions. Pooled samples libraries were
780 sequenced with lane sequencing on Novaseq 6000 S4 (Novogene). The Cell Ranger
781 2.0.1 pipeline was used to align reads to the GRCh38 human reference genome and
782 produce count matrices for downstream pre-processing and analysis using the Seurat
783 v5.0.1 R package[37].
784
785 **UMAP calculations and cell type annotations**
786 For analysis of CbO samples we implemented stringent quality filtration, only cells with
787 fewer than $5x10^4$ total reads, lower than 10% mitochondrial reads, more than 750 and
788 less than 6500 detected features were retained for analysis. Expression values were
789 library size corrected to 10,000 reads per cell and log1p transformed, with Principal
790 component analysis (PCA) performed on the scaled data for the top 2000 variable
791 genes. Batch correction between cell lines was performed on principal components
792 using Harmony[38]. Uniform Manifold Approximation Projection (UMAP) embeddings,
793 Nearest Neighbours and cell clusters were then calculated in harmony-corrected PCA
794 space using 35 dimensions, and cells were clustered using FindClusters(). For Day 7
795 COs, FindClusters() resolution was set at 0.2, and for Day 35-49, where the UMAP
796 indicated a greater degree of cell type complexity, we instead set a resolution of 0.5
797 and used FindSubCluster(resolution = 0.1, algorithm = 1) to separate cluster 7 into two
798 distinct subclusters 7_0 and 7_1. Cluster marker genes were calculated using a
799 Seurat's in-bult Wilcoxon Rank Sum test (logfc.threshold = 0.25, min.pct = 0.1,
800 only.pos = T), and differential expression analysis across experimental conditions was
801 performed using MAST[39]. Initial clustering identified two clusters 13 and 14 which
802 represented hypoxic/glycolytic cells, common to all human brain organoids[40]. As has
803 been done previously[41], these cells were excluded from analyses and a new UMAP
804 was calculated.
805 For analysis of engineered CbO and CbO co-cultures containing CHLA-01-Med and
806 Med211FH MB medulloblastoma (MB) cells or control NSC37.5 cells, we changed the
807 detected feature threshold greater than 500 and less than 7500, with no batch
808 correction was necessary. For engineered CbO UMAPs and Nearest neighbours were
809 calculated using 30 PCA dimensions and FindClusters() was run with a resolution of
810 0.5. For CbO co-cultures we used 15 PCA dimensions and a resolution of 0.35.

811 Malignant CHLA-01-Med and Med211FH MB cells were distinguished from co-
812 cultured CbO cells based on Leiden clustering and inferred copy number variants, with
813 co-cultured NSC73.5 identified based on clustering and marker gene expression
814 alone. InferCNV was run on CbO-CHLA-01-Med and CbO-Med211FH samples using
815 D49 CbO cells as a reference, the "subclusters" analysis mode, and setting the
816 following parameters: cutoff=0.1, k_obs_groups = 3, leiden_resolution = $1x10^{-5}$. For
817 annotating engineered CbO and organoid cells from CbO-MB co-cultures we used the
818 processed R object from the D35-49 CbO (Fig1B) as a reference, and the default
819 settings of Seurat FindTransferAnchors(), TransferData() and AddMetaData()
820 functions. We then annotated new cluster names based on their composition of
821 transferred cell type labels Fig S2D-G.
822
823 Finally, for the analysis of MB cells alone, cells CHLA-01-Med and Med211FH
824 identified by InferCNV were subset, and reanalysed using the standard Seurat
825 pipeline; UMAPs and nearest neighbours were calculated using 20 PCA dimensions
826 and FindClusters() was run with resolution=0.225.
827
828 **scRNA-Seq Analysis: Comparison to reference datasets**
829 To approximate the transcriptomic age of our CbO we compared data from this study,
830 and three other cerebellar organoid studies: Nayler et al[25], Chen et al[26], and Atamian
831 et al[24] against four datasets derived from developing foetal cerebellum: Aldinger et
832 al[42], Luo et al[16], Zhong et al[43], and Sepp et al[44]. First, pseudo-bulk transcriptomic data
833 were generated from aggregated single cell counts for all samples, and expressed as
834 log(counts per million +1). Data was merged and batch correction between different
835 sequencing methodologies (scRNAseq vs snRNAseq) was performed using Combat()
836 from the sva.3.48 package. We next derived an 'ageing-signature' as the top 200
837 genes correlated with age across the foetal cerebellum samples. This signature was
838 then used to compute the average Pearson correlation between CbO and foetal
839 cerebellum samples at different weeks of development.
840
841 To aid with D35/49 CbO cell type annotations, we compared cluster marker signatures
842 against those from the four foetal cerebellum datasets. In each case we obtained
843 published count matrices, UMAP-embeddings and author-defined cluster meta data,
844 and used them to perform a Wilcoxon Rank Sum test with Seurat's FindAllMarkers()
845 command (logfc.threshold = 0.25, min.pct = 0.1, only.pos = T) to obtain the list of

marker genes for their cell types. Then, for each dataset and marker gene, cluster specificity scores were computed (mean normalized counts per cluster/total mean normalized counts) – with overlapping gene signature specificity scores compared across studies by Pearson correlation. We performed the same analysis on CHLA-01-Med and Med211FH cells to determine each MB cluster's closest analogues from developing foetal cerebellum samples.

To compare CHLA-01-Med and Med211FH MB cells in co-cultures to patient tumours, we generated pseudo-bulk transcriptomic data from aggregated single cells counts from our co-cultured MB samples, and 36 patients in Hovestadt et al[45]. Combat batch correction was performed between log(cpm+1) transformed data, and Pearson correlation between samples were calculated across the top 2500 most variable genes (ranked by standard deviation). Pearson correlation across the same gene list was also used to query the relative similarity between patient tumours and CbO co-cultured CHLA-01-Med cells profile here, and CHLA-01-Med cells we previously cultured *in vitro* and profiled by RNAseq[35]. For Med211FH MB cells, we compared CbO co-cultured to RNAseq data from an *in vitro* sample drawn from the literature[17] and a second *in vitro* sample profiled as part of this study.

scRNA-Seq Analysis: Reference gene set/signature scoring

For reference signature scoring, average gene module expression was calculated for each single cell, subtracted by the aggregated expression of a random control set of features selected from the same average expression bins as the query genes[46] using Seurat's AddModuleScore() function. G/S and G2M gene modules are included in the Seurat v5.0.1 package; G3 RL.PRC and G4 RL.UBC Medulloblastoma cell of origin signatures were taken from Smith et al[14]; Group 3 and 4 MB tumour signatures were taken from Vladoiu et al[47]; WNT, SHH and G3/4 MB cell state signatures were taken from Hovestad et al[45]. For gene set enrichment analysis, gene sets were obtained from MolSigDB[48] and computations were performed using the R package fGSEA v4.4[49]. Gene ontology enrichment analysis of was performed on upregulated (p.adj<0.05, and avg_log2FC>2) genes in the MYC^{oe} cluster of engineered CbOs using the topGO v2.52.0 and org.Hs.eg.db v3.17.0 R packages.

Processed cell count and metadata from patient-derived MB samples was accessed from Hovestadt et al[45] and reanalysed in Seurat using default settings. The resulting

881 R object was then used as a reference, with the default settings of Seurat
882 FindTransferAnchors(), TransferData() and AddMetaData() functions to assign MB
883 Group3 and Group4 prediction scores to the co-cultured CHLA-01-Med and
884 Med211FH MB cells. To generate a Myogenic MB state signature, we took the
885 intersect of significant MB marker genes with avg_log2FC>1 from cluster 4 (CHLA-01-
886 Med) and cluster 6 (Med211FH). The processed reference R object from Hovestadt et
887 al[45] was then scored for the Myogenic MB state signature as detailed above using the
888 the AddModuleScore() function. Next, the Hovestadt et al[45] data was subset to group
889 3 samples, before Harmony[38] batch correction between samples was performed. New
890 UMAP embeddings, Nearest Neighbours were then calculated in harmony-corrected
891 PCA space using 15 dimensions, and clusters were identified using a resolution of 0.5.
892 We also inspected a large reference dataset of 763 bulk MB RNAseq samples (Cavelli
893 et al[1]) for expression of the Myogenic MB state signature using the GSVA 1.48.3 R
894 package[50]. Survival analysis was performed on patients with complete data (i.e. that
895 had died) using the survival_3.8-3 and survminer_0.5.0 R packages and splitting
896 patients into the Myogenic Signature High or Low groups based on the median
897 signature score.
898

899 **Cell lineage trajectory analysis**

900 For RNAvelocity analysis, velocyto[51] was used to calculate spliced and unspliced
901 transcriptomes, before subsequent analysis using scVelo[52], on Seurat-defined cell
902 types and UMAP embeddings, using default parameters. For single cell lineage
903 trajectory analysis, we imported the processed Seurat object into the Monocle3 R
904 package. The 'learn_graph' function was applied to infer single cell trajectories setting
905 close_loop = TRUE, minimal_branch_len to 10 and euclidean_distance_ratio to 1.5.
906 The 'order_cells' function was then used to set Progenitors and Cyc_Progenitors as
907 the root of states of pseudotime. Next we subset data to cell types involved in the G3
908 trajectory (early_RL/NSCs, glut_progenitors and matCN2) or G4 trajectory (NSCs,
909 GN/UBC_progs and GN/UBC)[53]. For each subset, the 'learn_graph' function was
910 applied again to infer single cell trajectories setting minimal_branch_len to 10 and the
911 'order_cells' function was used to select early_RL/NSCs and NSCs as the root states
912 of pseudotime. Differential gene expression was calculated across single cell
913 trajectories using Moran's I test. For each trajectory, the top 2500 most differentially
914 expressed genes over pseudotime were selected, and smoothened, alra-imputed[54]
915 expression over pseudotime was plotted.

916

917 **Receptor Ligand Modelling**

918 For receptor-ligand analysis, cell type meta data and count data for the top 15000
919 most highly variable genes in the CbO-MB dataset was input into CellphoneDB v5[55]
920 and run using the statistical_analysis mode.

921

922 **DNA methylation analysis**

923 All CbO and human cerebellar DNA samples underwent standard BSC conversion at
924 UCL Genomics facility (UCL, Great Ormond Street Institute of Child Health) and were
925 submitted for Illumina Methylation EPIC v2 array following standard protocols. Quality
926 control was performed and probe beta values were extracted from raw .idat files using
927 wateRmelon R package[56] under reference genome hg38. Probes with detection p-
928 values greater than 0.05 were removed using pfilter(), as well as probes associated
929 with sex chromosomes, mitochondrial chromosomes and single nucleotide
930 polymorphisms. Adjusted Dasen normalisation was then performed.

931

932 **Cerebellar Organoid developmental staging (DNA methylation)**

933 To stage the development of CbO compared with human cerebellar samples, an
934 'ageing signature' approach was applied, with the top 1% of probes whose beta values
935 best correlated to age in human cerebellar samples selected for subsequent
936 correlation with CbO probe betas. Combat batch correction was first performed
937 between CbO and human samples before top 1% probe selection and correlation to
938 CbO. To corroborate this approach, CbO methylation data adapted to EPIC v1 array
939 probe annotation was also passed to the foetal brain clock (FBC), an R package
940 specifically trained on foetal brain samples during development to estimate their
941 epigenetic age[57].

942

943 **Differentially and variably methylated probes and regions analysis**

944 Differentially methylated probes (DMPs) and regions (DMRs) were calculated pairwise
945 for CbO samples between comparison groups using the R package DMRcate[58] with
946 FDR threshold of 0.01. Additional criteria for DMR identification were set such that
947 DMRs must contain at least 6 CpG sites with <400 base pair separation. Variable
948 methylated probes (VMPs) and regions (VMRs) across CbO and human development
949 timepoints were identified within the DMRcate package using the same thresholds as
950 stated above for DMR analysis and the top 5% VMP/VMRs defined as significant.

951 VMRs were then annotated to genes (VMGs), after which significant VMGs were
952 clustered based on z-scores of average beta-values of the probes contained within
953 them and taken for pathway analysis.
954
955 **DNA methylation: Comparison to reference datasets**
956 For human rhombic lip (RL) and external granular layer (EGL) correlation, raw .idat
957 files for micro-dissected RL and EGL samples were accessed from GSE207266[14] and
958 processed using the same raw data processing pipeline adapted for EPIC v1 array
959 annotation before downstream analysis. DMPs were identified between each
960 cerebellar compartment (n=7) as stated above with FDR threshold of 0.01. DMPs were
961 then subset to CbO average probe betas adapted to EPIC v1 array annotation and
962 correlated to each cerebellar compartment.
963 For CbO editing samples, reference 450K methylation data of 763 MB samples were
964 accessed from GSE85218[1]. CbO datasets were trimmed to probes present in both
965 450K and EPICv2 array and clustering of CbO and MB samples was performed based
966 on a published probe set shown to distinguish between MB subgroups[59] (34/48 CpG
967 probes present in QC filtered datasets). DMPs were calculated as described above on
968 the trimmed CbO dataset then correlated to patient MB samples.
969
970 **scRNA-Seq/DNA methylation integration and pathway analysis**
971 Differentially expressed genes (DEGs) between Day 7 and Day 35 CbO scRNA-Seq
972 data with adjusted p-value < 0.05 and absolute log2FC > 0.25 were integrated with
973 genes mapping to DMRs from methylation data at matched timepoints with p-value <
974 0.05 and greater than a 10% imposed threshold in methylation difference. Genes
975 demonstrating concordant hypermethylation and down-regulation or hypomethylation
976 and up-regulation were taken for subsequent pathway analysis. For pathway analysis,
977 gene lists were input into Gprofiler [60] and pathways calculated based on a Benjamini-
978 Hochberg FDR < 0.05. Pathway visualisation was performed using CytoScape [61]. For
979 scRNA-Seq upon MB co-culture pathway analysis, UMAP clusters were grouped
980 based on cell developmental state (un/differentiated) and effect of MB co-culture on
981 cluster percentage (increase/decrease). Common pathways from each group were
982 then identified and the top 100 most significant (adjusted-p<0.05) Reactome and
983 KEGG pathways were plotted. For VMR pathway analysis, the top 100 most significant
984 (adjusted-p<0.05) GO:Biological Process and GO:Molecular Function pathways were
985 plotted for human and CbO VMG clusters, whilst for overlapping pathways with

concordant DMR/DEG integration of Day 7 vs Day 35 CbO samples, GO:Cell Compartments were also plotted.

Ethics

Ethical approval for the work on human cerebellar samples was obtained from Brain UK, reference number 22/010.

Table 1 Primers used for RT-qPCR reactions

Gene	Forward Primer (5'-3')	Reverse Primer (5'-3')
ACTIN B	GCGAGAAGATGACCCAGATC	CCAGTGGTACGGCCAGAGG
GAPDH	CAATGACCCCTTCATTGACC	GACAAGCTTCCCGTTCTCAG
NESTIN	GAAACAGCCATAGAGGGCAAA	TGGTTTTCCAGAGTCTTCAGTGA
SOX1	TGCTTGTTCTGTTAACTCAC	AAAGAACCTCAGAGAGAGTC
EN2	CCGGCGTGGGTCTACTGTA	GGCCGCTTGTCCTCTTTGTT
OTX2	AGAGGACGACGTTCACTCG	TCGGGCAAGTTGATTTTCAGT
KIRREL2	ACAACTCTCCTTATGGTCATC	ATTCGCATCAGGTTCTTTTG
OLIG2	GACAAGCTAGGAGGCAGTGG	CGGCTCTGTCATTTGCTTCTTG
SKOR2	CCAGGTGTTAAAAGGAAACACA	GCTCCCTTTTCATCTGATCCT
PAX6	AGAGAATACCAACTCCATCAG	GATAATGGGTTCTCTCAAACTC
ATOH1	TGTTATCCCGTCGTTCAACAAC	TGGGCGTTTGTAGCAGCTC
BARHL1	GAGCGGCAGAAGTACCTGAG	GTAGAAATAAGGCGACGGGAAC
EOMES	CACATTGTAGTGGGCAGTGG	CGCCACCAAACTGAGATGAT
MYC	AGTGGAAAACCAGCAGCCTC	TTCTCCTCCTCGTCGCAGTA
GATA6	GCCAACTGTCACACCACAAC	TCATAGCAAGTGGTCTGGGC
NANOG	AGAAAAACAACTGGCCGAAGAAT	GTTGAATTGTTCCAGGTCTGGTT

Table 2 Primary antibodies and dilutions used for immunohistochemistry

Primary Antibody	Dilution
SOX2 (abcam, ab97595)	1:500
OLIG2 (Santa Cruz, sc-19967)	1:200
CALB (Swant, CB300)	1:200
NeuN (Chemicon, MAB377)	1:500
EOMES (Chemicon, AB15894)	1:200
KI67 (abcam, ab15580)	1:500
GFP (Chemicon, AB16901)	1:400

cCASP3 (Cell Signalling, 9664)	1:500
MAP2 (Sigma, M4403)	1:200
TubIII (abcam, ab7751)	1:200
Myogenin (abcam, ab1835)	1:100

997

Acknowledgements

This work is funded by grants from Brain Tumour Research (Centre of Excellence award to S.M.), Cancer Research UK (C23985/A29199 programme award to S.M.), Barts Charity (MGU0447 programme grant to S.M.). We thank Gary Warnes (Blizard Flow Cytometry Core Facility), Maeve McLaughlin (Blizard Advanced Light Microscopy Facility), Imran Uddin (Single Cell Genomics Facility, UCL, Cancer Institute), Myrianni Constantinou and Sara Lucchini for sharing their expertise. The collection and annotation of FFPE human tissue samples are funded by the NIHR GOSH BRC. The collection of fresh frozen human tissue samples is funded by the MRC-Wellcome Trust HDBR.

Author contribution

SB and SM conceived and supervised the project; TW, SB and SM designed the experiments; TW performed, analysed and interpreted all experiments and data; SB analysed and interpreted all experiments and data; JN analysed and interpreted scRNA-seq data; TW and YX analysed DNA methylation data; OO, TM and AM identified and provided suitable human foetal cerebellar samples; BD and LD shared G3 MB primary cells, datasets and expertise; NRZ contributed expertise for DNA methylation analysis; SM secured financial support; TW, SB, JN and SM wrote the paper with contributions from all authors.

Competing interests

The authors declare no competing interests for this study.

Data Availability

The authors declare that all the data supporting the findings of this study are available within the article and its supplementary files. The scRNA-seq and DNA methylation datasets generated in this study and processed data are available in the NCBI Gene Expression Omnibus database (GSE263652 and GSE263653 respectively) or are available from the corresponding authors upon reasonable request. Publicly available datasets used in the study were retrieved from relevant databases as outlined in materials and methods.

Code Availability

The authors declare that no custom code was used in this study. A full description of analyses including functions and packages used are stated in the materials and methods. Specific code will be made available from the corresponding authors upon reasonable request.

Figures and Legends



Figure 1. CbO is composed of diverse cerebellar lineages and displays characteristic structural organisation.

A. Schematic of CbO samples used to assess expression of cerebellar markers.

B. H&E staining of CbO_19 and CbO_61 showing formation of characteristic flat-oval neural rosettes within each structure.

C. Heatmaps showing average expression of marker genes associated with cerebellar differentiation up to Day 35 (D35) of development for CbO_19 and CbO_61 derived from two independent EPSC lines (D0). Heatmaps show Z-scores for average dCT values from n = 3 independent batches of CbO.

D. Representative immunofluorescence staining of OLIG2$^+$ GABAergic progenitors (red), Calbindin$^+$ (CALB$^+$) mature neurons (pink) and SOX2$^+$ neural stem and progenitor cells (green) in D35 CbO_61.

E. Representative immunofluorescence staining of NeuN$^+$ glutamatergic neuronal cells (red) and SOX2$^+$ neural stem and progenitor cells (green) in D35 CbO_61.

F. Schematic of CbO samples used in single cell RNA-Seq (scRNA-Seq) analysis.

G. Uniform manifold approximation and projection (UMAP) plot of scRNA-Seq data from CbO_19 and CbO_61 at Day 35 and CbO_61 at Day 49 of differentiation (left) and bar plots showing percentages of annotated cell populations identified (right).

H. Dot plot showing key marker genes used to identify major cell types in CbO (see also Figure S1M).

Scale bars = 150 µm (B) and 100 µm (D and E).


A
Day 0
7
14
21
28
35
DNA Methylation
B
1
2
3
4
5
Day 7
Day 14
Day 21
Day 28
Day 35
Methylation Z-score
2
-2
POUF51
PAX2
PAX5
FGF2
RBFOX3
SOX1
OTX1
LMX1A
EN1
MEIS1
PAX6
OTX2
MAP2
GRIP1
SOX30
FGFR2
MAP4
MAP7
C
Clusters:
1
2
3
4
5
Regulation of Receptor Activity
Transmembrane Transporter Activity
ECM Organization
Neurogenesis
Transcription Corepressor
GTPase-mediated Transduction
Small Molecule Binding
Embryogenesis
Organ Development
Nucleotide Binding
Signal Transduction
Proliferation
Neuron Projection
Mesodermal Fate Specification
Cytoskeleton
Microtubule Organizing Center
Synaptic Junction
Cell Adhesion
Nervous System Development
Catalytic Activity
Positive Regulation of Reactive Oxygen Species
D
CbO VMG
1624
1086
1467
Human VMG
D7
D14
D21
D28
D35
Pearson Correlation
0.1
0
-0.1
cs22
cs23
9pcw
10pcw
11pcw
12pcw
13pcw
14pcw
15pcw
16pcw
17pcw
19pcw
20pcw
23pcw
25pcw
26pcw
28pcw
29pcw
30pcw
34pcw
35pcw
36pcw
37pcw
E
MAP2
PAX6
MAP4
GRIP1
Expression Log2 FC (D35 vs D7)
Differential Methylation (D35 vs D7)
15
10
5
0
-5
-10
-15
-0.5
0.0
0.5

1070

1071

1072 ***Figure 2. CbO development is epigenetically regulated similarly to human***
1073 ***cerebellum.***

1074 A. Schematic of CbO samples used to assess DNA methylation during
1075 development.

1076 B. Heatmap showing k-means clustering (n=5) of significant variable methylated
1077 genes across 35 days of CbO maturation. Mean beta values were taken for
1078 each timepoint from CbO_19 and CbO_61. Z-scores for average beta values
1079 of probes contained within each gene are plotted, with key cerebellar
1080 developmental and neuronal genes annotated.

1081 C. Bubble plot showing top 100 significant (adjusted p-value < 0.05) GO
1082 Biological Processes and Molecular Functions of genes from 5 clusters shown
1083 in **B**. Bubbles are coloured based on each cluster and size is proportional to
1084 number of genes in specific GO term.

1085 D. Venn diagram showing 1086 common variably methylated genes (VMGs)
1086 calculated through human (Carnegie stage 22 to 37 post conception weeks)
1087 and CbO (CbO_19 and CbO_61, Day 7 to 35) development (Upper). Pearson
1088 correlation of human and CbO samples on their beta values for 1086 common
1089 VMGs.

1090 E. Volcano plots of differentially expressed (DEG) and differentially methylated
1091 (DMG) genes between D35 and D7 of CbO maturation. Orange and green
1092 dots represent upregulated/hypomethylated and
1093 downregulated/hypermethylated genes respectively. Genes found in VMG
1094 clusters in B are highlighted.

1095

1096

1097


A
cs22
cs23
9pcw
10pcw
11pcw
12pcw
13pcw
14pcw
15pcw
16pcw
17pcw
19pcw
20pcw
23pcw
25pcw
26pcw
28pcw
29pcw
30pcw
34pcw
35pcw
36pcw
37pcw
D7
D14
D21
D28
D35
Pearson Correlation
0.8
0
B
Atamian et al.
Chen et al.
Nayler et al.
This study
D60.1
D60.2
D60.3
D55.1
D55.2
D55.3
D55.4
D80.1
D80.3
D80.4
D156.1
D156.2
D156.3
D156.4
D90-Con1
D90-Con2
D90-Con3
D90-MG1
D90-MG2
D90-MG3
D7-CbO19
D7-CbO61
D35-CbO19
D35-CbO61
D49-CbO61
7pcw
8pcw
9pcw
10pcw
11pcw
12pcw
13pcw
14pcw
15pcw
16pcw
17pcw
18pcw
20pcw
21pcw
27pcw
40pcw
Pearson Correlation
1
0.4
C
RL^SVZ Expression Signature
Cyc_progenitors
Purkinje
NSCs
Meninges
Berg_Glia
GN/UBC_progs
Roof_Plate
Progenitors
GN/UBC
GPC
matCN1
early_RL/NSC
glut_progenitors
Ependymal /ChP
matCN2
UMAP.2
UMAP.1
Score
1.0
0.5
0.0
D
RL
EGL
D7
D14
D21
D28
D35
Pearson Correlation
0.65
0.45
E
UBC RL^SVZ Signature
Score
0.9
0.3
-0.3
UMAP.2
UMAP.1
F
Photoreceptor RL^SVZ Signature
Score
0.4
0.2
0.0
G
Nuclei
KI67
EOMES
H
% Ki67+ EOMES+ cells in CbO
6
4
2
0
***
inside rosette
outside rosette
I
PRTG^High
SOX2
NESTIN
Nuclei
J
% SOX2+ PRTG^High cells in CbO
15
10
5
0
***
inside rosette
outside rosette
K
G3 Lineage
G4 Lineage
Expression
Pseudotime
Gene
OTX2
SOX2
PRTG
NES
MYC
EOMES
PAX6
SLC17A6

1098

1099

1100 ***Figure 3. CbO displays spatiotemporal expression of G3/G4 MB cell-of-origin.***

1101 A. Heatmap showing correlation of methylation status of top 1% (6886) age-
1102 dependent CpG probes between human developing cerebellum samples and
1103 CbO (see also Figure S3A).

1104 B. Heatmap showing correlation of top 1% (200) age-related genes between
1105 pseudo-bulk RNA-Seq of CbO and cerebellar organoids from previously
1106 published protocols[24-26] and human foetal cerebellar samples[16,42-44] calculated
1107 similarly to described above.

1108 C. UMAP plot of scRNA-Seq data from CbO at Day 35-49 of differentiation
1109 showing signature score for rhombic lip subventricular zone (RL^{SVZ}) signature
1110 genes[15].

1111 D. Heatmap showing correlation of average beta values of CbO to human
1112 microdissected rhombic lip (RL) and external granule layer (EGL) regions[15] for
1113 differentially methylated probe set calculated between RL and EGL samples.

1114 E. UMAP plot of scRNA-Seq data from CbO at Day 35-49 of differentiation
1115 showing signature score for unipolar brush cell (UBC) RL^{SVZ} signature
1116 genes[15].

1117 F. UMAP plot of scRNA-Seq data from CbO at Day 35-49 of differentiation
1118 showing signature score for photoreceptor RL^{SVZ} signature genes[15].

1119 G. Representative immunohistochemistry pictures of D35 CbO_61 showing a
1120 neural rosette with cells positive for EOMES (green) and Ki67 (red). Nuclei
1121 are sown in grey.

1122 H. Quantification of staining shown in G of Ki67+EOMES+ nuclei with respect to
1123 CbO neural rosette structures**.** students t-test ****$p<0.0001$. n = 5 regions of
1124 interest quantified.

1125 I. Representative immunohistochemistry pictures of D35 CbO_61 showing a
1126 neural rosette with cells positive for PRTG (green), SOX2 (red) and NESTIN
1127 (light blue). Nuclei are shown in grey.

1128 J. Quantification of staining shown in **I** of SOX2+$PRTG^{High}$ nuclei with respect to
1129 CbO neural rosette structures**.** $PRTG^{High}$ was defined as the top 50% of
1130 fluorescence signal for each image. students t-test ****$p<0.0001$. n = 5
1131 regions of interest quantified.

1132 K. Defined Group 3 (G3) and 4 (G4) medulloblastoma cell-of-origin trajectories
1133 selected for further analysis (G3 = early_RL/NSC, glut_progs, matCN2; G4 =
1134 NSCs, GN/UBC_progs, GN/UBC; see Figure 1H). Expression of genes
1135 associated with G3/4 medulloblastoma across each of the G3 and G4
1136 trajectories.

1137

1138

1139


A
DOX
Day 0
35
63
pEOMES/pPAX6-rtTA-BFP
TRE-c-MYC-GFP
B
pEOMES;MYC-GFP
GFP Ki67 Nuclei
H&E
pPAX6;MYC-GFP
GFP Ki67 Nuclei
H&E
C
Cyc_progenitors
Progenitors
Roof_Plate
Berg_Glia
NSCs
early_RL/NSC
glut_progenitors
GN/UBC_progs
GN/UBC
GPC
matCN1
matCN2
Purkinje
Ependymal/ChP
Meninges
MYCOE
UMAP.2
UMAP.1
D
MYC Expression
matCN1
Purkinje
GN/UBC
GPC
Ependymal/ChP
glut_progenitors
GN/UBC_progs
matCN2
early_RL/NSC
MYCOE
NSCs
Progenitors
Meninges
Cyc_progenitors
Roof_Plate
Berg_Glia
3
1
E
Oncogene-induced Cell Senescence
Oxygen Transport
Protein-DNA Complex Disassembly
Stem Cell Proliferation
Positive Regulation of DNA Mehytlation
Chromatin Remodelling
Inositol Phosphate-mediated Signalling
Notch Signalling Pathway
0
5
10
-log(Fisher)
F
MB Lineage
G3 lineage
G4 lineage
MYCOE Cells
pEOMES-MYCOE
pPAX6-MYCOE
G
MIK67
NPW
HMGA1
MATK
MYC
OTX2
PRTG
NES
ATOH1
SOX2
Percent Expressed
25
50
75
Average Expression
1
0
-1
G4 lineage
G3 lineage
pEOMES-MycOE
pPAX6-MYCOE
H
G3/4 lineage
MYCOE
Mean Signature Score
0.8
0.6
0.4
0.2
0.0
****
WNT
SHH
G3/4
I
G3/4 MB Signature Score
0.8
0.6
0.4
0.2
0.0
****
G3 lineage
pPAX6-MYCOE
G4 lineage
pEOMES-MycOE
J
MB Poor Prognosis
p.adj=2.09x10-11
NES=3.46
enrichment score
rank
K
pEOMES-MYCOE
pPAX6-MYCOE
pEOMES.CTRL
pPAX6.CTRL
Z-score
2
0
-2
BARHL1
CHD7
PRDM6
TBR1
LMX1A
MATR3
OTX2
GFI1
PAX3
BFA2T2
L
FABP3
HMGA1
SLC7A5
BARHL1
CHD7
SALL2
GRIA2
NEUROD2
Expression Log2 FC
Differential Methylation
4
2
0
-2
-4
-0.5
0.0
0.5

1140

1141 ***Figure 4. Edited medulloblastoma lineages-of-origin display features of MB***
1142 ***dysregulation upon MYC overexpression***

1143 A. Schematic of cerebellar organoid (CbO) editing strategy (see Methods).

1144 B. Representative immunohistochemistry staining for GFP (green) and Ki67
1145 (red) (left) and haematoxylin and eosin staining (right) for CbO_19 collected
1146 at Day 63 of differentiation for dox-induced *pEOMES;MYC-GFP* and
1147 *pPAX6;MYC-GFP* organoids.

1148 C. UMAP plot of scRNA-Seq data from *pEOMES;MYC-GFP, pPAX6;MYC-GFP*
1149 and control CbOs at Day 63 of differentiation and colour by cell type.

1150 D. UMAP shown in D with *MYC* expression plotted.

1151 E. Gene ontology enrichment bar plot of MYC^{OE} cluster marker genes.

1152 F. UMAP plot of control D35/40 CbO scRNA-Seq data highlighting Group3 (red)
1153 and Group4 (green) MB lineages of origins (Top). Projection of MYC^{OE} cells
1154 from D63 *pEOMES;MYC*-GFP (blue) *and pPAX6;MYC-GFP* (purple) CbOs
1155 onto control UMAP embeddings.

1156 G. Dot plot showing G3 and G4 lineage-of-origin marker and MB-associated
1157 genes in G3/4 lineage genes compared to MYC^{OE} cells from D63
1158 *pEOMES;MYC-GFP and pPAX6;MYC-GFP* CbOs.

1159 H-I. Violin plot showing mean signature scores for WNT, SHH or G3/G4 MB
1160 subgroups[45] in G3/4 lineages-of-origin and MYC^{OE} cells from D63
1161 *pEOMES;MYC-GFP and pPAX6;MYC-GFP* cells CbOs.

1162 J. Gene set enrichment plot of the
1163 POMEROY_MEDULLOBLASTOMA_PROGNOSIS_DN gene set in the
1164 MYC^{OE} cell compared to G3/4 lineages-of-origin, NES=3.46, padj=2.09E-11

1165 K. Heatmap showing z-scored average beta values of probes contained within
1166 differentially methylated genes between MYC^{OE} (*pEOMES;MYC-GFP,*
1167 *pPAX6;MYC-GFP)* and control medulloblastoma lineage-of-origin samples
1168 (*pEOMES.*ctrl, *pPAX6.*ctrl). Key cerebellar and medulloblastoma associated
1169 genes are annotated.

1170 L. Scatter plot of differentially expressed (DEG) and differentially methylated
1171 (DMG) genes between MYC^{OE} cells and G3/4 cell-of-origin. Orange and green
1172 dots represent upregulated/hypomethylated and
1173 downregulated/hypermethylated genes respectively.

1174

1175

1176

1177


A
Days in Co-Culture
Day 7
35
49
scRNA-Seq
Day 1
Day 4
Day 7
Day 14
Nuclei
MB cells
B
% Ki67+ MB cells
ns
ns
CHLA-01-Med.D7
CHLA-01-Med.D14
Med211FH.D7
GFP+ MB cells
Ki67
Nuclei
CHLA-01-Med D14
Med211 FH D14
C
CbO
NSC73_5
CHLA-01-Med
Med211FH
UMAP.2
UMAP.1
CbO
CbO-NSC73_5
CbO-CHLA-01-Med
CbO-Med211FH
D
CHLA-01-Med
Med211 FH
Mean Signature Score
****
WNT
SHH
G3/4
E
Group
CbO-CHLA-01-Med.1
CbO-CHLA-01-Med.2
CbO-Med211FH.invitro
CbO-Med211FH.PDX
Pearson Correlation
MB Subgroup
?
G3
G4
SHH
WNT
F
CHLA-01-Med
Med211 FH
Pearson Correlation
2D CbO-MB
2D CbO-MB

1178

1179

1180 ***Figure 5. CbO enables MB growth whilst also retaining MB transcriptional***
1181 ***profiles closer to those of patient tumour samples.***

1182 A. Schematic of protocol used to co-culture cerebellar organoids (CbO) with
1183 medulloblastoma (MB) showing CbO-MB sample used for scRNA-Seq (left
1184 panel). Representative immunofluorescence staining of GFP^+ CHLA-01-Med
1185 MB cells upon one, four, seven and fourteen days of co-culture with CbO_61,
1186 scale bars = 100 µm (right panels).

1187 B. Box and whisker plot showing percentage of MB cells (GFP^+) expressing the
1188 proliferative markers Ki67 upon 7 and 14 days of co-culture in CHLA-01-Med
1189 and Med211FH cells. Graphs report mean ± SEM, unpaired t-test, n = 6
1190 independent CbO-MB analysed, ns = not significant (left). Representative
1191 immunofluorescence staining of GFP^+ and $KI67^+$ MB cells upon 14 days of co-
1192 culture with CbO, scale bars = 100 µm (right).

1193 C. UMAP plot of scRNA-Seq data from D49 control CbO_61, CbO-Med211-FH,
1194 CbO-CHLA-01-Med and control CbO-NSC73_5 co-cultures, coloured by
1195 genotype (left). Barplot showing proportion of cells from each genotype in the
1196 different experimental models (right).

1197 D. Violin plot showing signature scores for WNT, SHH or G3/G4 MB subgroups[45]
1198 in CbO-MB. One-way ANOVA ****$p<0.0001$.

1199 E. Heatmap showing correlation scores between expression of pseudo-bulk
1200 RNA-Seq of MB fractions only from CbO-Med211-FH and CbO-CHLA-01-Med
1201 and reference MB samples. Clustering based on expression profile has been
1202 used to assess molecular subgroup of CbO-MB models.

1203 F. Boxplots plot showing correlations between same MB cell line grown as 2D
1204 (red) or 3D (blue) model and MB samples shown in D. One-way ANOVA
1205 ****$p<0.0001$.

1206

1207

1208

1209


A
CHLA-01-Med
Med211FH
UMAP.1
UMAP.2
B
Seurat Clusters
CbO-CHLA-01-Med.1
CbO-CHLA-01-Med.2
CbO-Med211FH_invitro
CbO-Med211FH_PDX
C
CHLA-01
Med211 FH
Glial/Stem
Myogenic
MKI67
RPS4AY1
APOE
SIX3
NEUROD4
MYC
SYT1
TMSB4X
NEUROD1
PTN
FEZ1
ID4
SOX2
NTRK2
NES
MYOG
MYOD1
KLHL41
TNNT1
MYL4
IL17B
Percent Expressed
Average Expression
D
MB Cells
CHLA-01-Med
Med211FH
Pearson Correlation
E
Cluster 8
Cluster 5
F
Cluster 6
Cluster 4
Regulation of Neuron Differentiation
Neg. Regulation of B Cell Differentiation
Limbic System Development
Neg. Regulation of Neurogenesis
Pos. Reg. of Neuron Projection Dev.
Neuron Projection Morphogenesis
Muscle Organ Development
Skeletal Muscle Contraction
Muscle Contraction
Sarcomere Organisation
Pos. Reg. of Myoblast Differentiation
Muscle Structure Development
OddsRatio
-log(Fisher)
G
GFP+MB cells
MYOGENIN Nuclei
H
Myogenic Signature Score
WNT SHH G3 G4
I
G3 MBs:
Myogenic Signature Score
J
State
Myogenic
Other
MUV29
MUV11
Icb1299
Med2112FH
Med211FH
Icb1572
Med411FH
SJ17
RCMB20
BCH825
MUV34
BCH1205
Med114FH
Med2312FH
SJ617
SJ917
K
Myogenic Signature Score
WNT SHH G3 G4
L
Myogenic Signature Score
WNTα
WNTβ
SHHα
SHHβ
SHHγ
SHHδ
G3α
G3β
G3γ
G4α
G4β
G4γ
M
Myogenic Signature HIGH
Myogenic Signature LOW
Survival Probability
Time (Years)
p=0.0059

1210

1211 ***Figure 6 CbO-MB uncovers a subset of Group3 MB cells with a myogenic***
1212 ***transcriptional state.***

1213 A. UMAP plot of scRNA-Seq data from MB cells only from D49 CbO-Med211-FH
1214 and CbO-CHLA-01-Med CbO-MB co-cultures, coloured by genotype (top),
1215 and Louvain clusters (bottom).

1216 B. Barplot showing proportion of MB cells from each CbO-MB co-culture in each
1217 cluster.

1218 C. Dot plot showing key marker genes used to identify MB cell types in MB cells
1219 only from D49 CbO-Med211-FH and CbO-CHLA-01-Med CbO-MB co-
1220 cultures.

1221 D. Heatmap showing Pearson correlation of MB cell clusters across the top 250
1222 specific markers for each cluster.

1223 E. Venn diagram showing the intersect of CbO-Med211-FH cluster 8 and CbO-
1224 CHLA-01-Med cluster 5 marker genes (left). Gene ontology enrichment bar
1225 plot of the 44 shared markers between clusters 8 and 5 (right).

1226 F. Venn diagram showing the intersect of CbO-Med211-FH cluster 6 and CbO-
1227 CHLA-01-Med cluster 4 marker genes (left). Gene ontology enrichment bar
1228 plot of the 127 shared markers between clusters 6 and 4 (right).

1229 G. Immunohistochemistry of CbO-Med211-FH co-cultures stained for GFP
1230 (green) and myogenin (red). Scalebar = 10 µm.

1231 H. Violin plot showing signature scores for the myogenic signature in different
1232 MB subgroups of a reference cohort of patient MB scRNA-Seq data[45].

1233 I. UMAP plot of Group 3 MB reference samples in H, coloured by myogenic
1234 signature score, and labelled by their Louvain cluster.

1235 J. Barplot showing the relative proportion of myogenic (clusters 4 and 6) vs non-
1236 myogenic cells in Group 3 MB reference samples in H.

1237 K. Violin plot showing signature scores for the myogenic signature in different
1238 MB subgroups of a reference cohort of patient MB RNA-seq data[1].

1239 L. Violin plot showing signature scores for the myogenic signature in different
1240 MB subtypes of reference cohort of patient MB RNA-seq data in K

1241 M. Survival curve showing survival data of MB patients shown in K, split by
1242 myogenic high (> median, red) or myogenic low (< median, blue) signature
1243 score.

1244


A
Cyc_prog/NSCs
Progenitors
Ependymal/ChP
Meninges
GPC1
GPC2
MatCN
CHLA-01-Med
Med211FH
NSC73_5
UMAP.2
UMAP.1
B
Cyc_prog/NSCs
Progenitors
Ependymal/ChP
Meninges
GPC1
GPC2
MatCN
CbO-NSC73_5
CbO
CbO-CHLA-01-Med.1
CbO-CHLA-01-Med.2
CbO-Med211FH.invitro
CbO-Med211FH.PDX
C
GFP+MB cells
TUBIII cCASP3
GFP+MB cells
MAP2 cCASP3
D
CHLA-01-Med
Med211FH
NSC73.5
E
Mean Exp
Interacting Cells
Meninges
Ependymal/ChP
MatCN
GPC2
GPC1
Progenitors
Cyc Progs/NSCs
CHLA-01-Med
Med211 FH
F
NOTCH1SOX2GFP
NOTCH1DLL3GFP
G
BMI1i/MAPKi
IP6
Day 49
53
Viable cells
CbO-MB:
GFP+ MB cells
GFP- CbO cells
H
Viable cells
BMI1i/MAPKi
AUC (Area-Under-Curve)
I
relative proportion cCASP3+ cells
vehicle
treated
ns
GFP+ MB cells cCASP3 Nuclei
Vehicle
Treated
J
Viable cells
IP6
AUC (Area-Under-Curve)
K
relative proportion Ki67+ cells
vehicle
treated
ns
GFP+ MB cells Ki67 Nuclei
Vehicle
Treated

1245

1246 ***Figure 7. CbO-MB reveal cell-cell interactions and molecular events induced by***
1247 ***MB growth and they represent a suitable model for drug screening.***

1248 A. UMAP plot of scRNA-Seq data from D49 control CbO_61, CbO-Med211-FH,
1249 CbO-CHLA-01-Med and control CbO-NSC73_5 co-cultures, coloured by
1250 celltype.

1251 B. Barplot showing proportion of CbO cell types only present in control CbO_61,
1252 CbO-Med211-FH, CbO-CHLA-01-Med and control CbO-NSC73_5 co-
1253 cultures.

1254 C. Immunohistochemistry images of cerebellar organoids co-cultured with
1255 Med211FH for 14 days stained for GFP (green), cCASP3 (white) and
1256 MAP2(red, left) or TubIII (red, right). Scale bars = 10 µm.

1257 D. Venn diagram showing the shared significant receptor-ligand pairs modelled
1258 between co-cultured CbO-Med211-FH, CbO-CHLA-01-Med and CbO-
1259 NSC73_5 and CbO_61 cell types. Shared MB-specific receptor-ligand pairs
1260 are highlighted in bold and plotted in panel E.

1261 E. Dot plot showing significant 27 shared MB-specific receptor-ligand pairs
1262 identified by CellPhoneDB analysis interaction are separated by cell line CbO-
1263 CHLA-01-Med (top) CbO-Med211-FH (bottom), and direction MB cells as a
1264 source (left) or as a target (right). Points size corresponds to the co-
1265 expression value of the receptor-ligand pair and point colour corresponds to
1266 the interacting CbO cell type.

1267 F. Immunohistochemistry images of cerebellar organoids co-cultured with CHLA-
1268 01-Med MB cells for 14 days stained for predicted R/L interactions in E. Upper
1269 panel: NOTCH1 (green), SOX2 (red) and GFP (white); Lower panel: NOTCH1
1270 (green), DLL3 (red) and GFP (white). Scale bars = 5 µm.

1271 G. Schematic of combination treatment with PTC209 (BMI1i) and PD329501
1272 (MAPKi) or IP6 of CbO-CHLA-01-Med co-cultures.

1273 H. Viability assays of GFP^+ MB cells (green) and GFP^- CbO cells (pink) upon 4
1274 days of treatment with increasing concentrations of BMI1 and MAPK
1275 inhibitors. Measurement of Area Under Curve (AUC) to compare the overall
1276 response to treatment. n= 9 independent experiments. graphs report mean ±
1277 SEM, unpaired t-test ****$p<0.0001$

1278 I. Quantification (left) and representative images (right) of vehicle and treated
1279 CbO-CHLA-01 co-cultures from H stained for GFP and cCASP3. graphs
1280 report mean ± SEM, paired t-test **$p<0.01$; ns = not significant. n = 6 regions
1281 of interest quantified. Scale bars = 10 µm.

1282 J. Viability assays of GFP^+ MB cells (green) and GFP^- CbO cells (pink) upon 4
1283 days of treatment with increasing concentrations of IP6. Measurement of Area
1284 Under Curve (AUC) to compare the overall response to treatment. n= 5
1285 independent experiments. graphs report mean ± SEM, unpaired t-test
1286 ****$p<0.0001$

K. Quantification (left) and representative images (right) of vehicle and treated CbO-CHLA-01-Med co-cultures from J stained for GFP and Ki67. graphs report mean ± SEM, paired t-test **p<0.01; ns = not significant. n = 5 regions of interest quantified. Scale bars = 10 µm.

1292 **References**

1293 1. Cavalli, F.M.G., Remke, M., Rampasek, L., Peacock, J., Shih, D.J.H., Luu, B.,
1294 Garzia, L., Torchia, J., Nor, C., Morrissy, A.S., et al. (2017). Intertumoral
1295 Heterogeneity within Medulloblastoma Subgroups. Cancer Cell *31*, 737-754
1296 e736. 10.1016/j.ccell.2017.05.005.
1297 2. Northcott, P.A., Buchhalter, I., Morrissy, A.S., Hovestadt, V., Weischenfeldt, J.,
1298 Ehrenberger, T., Grobner, S., Segura-Wang, M., Zichner, T., Rudneva, V.A., et
1299 al. (2017). The whole-genome landscape of medulloblastoma subtypes. Nature
1300 *547*, 311-317. 10.1038/nature22973.
1301 3. Schwalbe, E.C., Lindsey, J.C., Nakjang, S., Crosier, S., Smith, A.J., Hicks, D.,
1302 Rafiee, G., Hill, R.M., Iliasova, A., Stone, T., et al. (2017). Novel molecular
1303 subgroups for clinical classification and outcome prediction in childhood
1304 medulloblastoma: a cohort study. The Lancet Oncology *18*, 958-971.
1305 10.1016/s1470-2045(17)30243-7.
1306 4. Sharma, T., Schwalbe, E.C., Williamson, D., Sill, M., Hovestadt, V., Mynarek,
1307 M., Rutkowski, S., Robinson, G.W., Gajjar, A., Cavalli, F., et al. (2019). Second-
1308 generation molecular subgrouping of medulloblastoma: an international meta-
1309 analysis of Group 3 and Group 4 subtypes. Acta Neuropathol *138*, 309-326.
1310 10.1007/s00401-019-02020-0.
1311 5. Mueller, S., and Chang, S. (2009). Pediatric brain tumors: current treatment
1312 strategies and future therapeutic approaches. Neurotherapeutics *6*, 570-586.
1313 6. Rechberger, J.S., Toll, S.A., Vanbilloen, W.J.F., Daniels, D.J., and Khatua, S.
1314 (2023). Exploring the Molecular Complexity of Medulloblastoma: Implications
1315 for Diagnosis and Treatment. Diagnostics (Basel) *13*.
1316 10.3390/diagnostics13142398.
1317 7. Thompson, E.M., Ashley, D., and Landi, D. (2020). Current medulloblastoma
1318 subgroup specific clinical trials. Transl Pediatr *9*, 157-162.
1319 10.21037/tp.2020.03.03.
1320 8. Badodi, S., Marino, S., and Guglielmi, L. (2019). Establishment and Culture of
1321 Patient-Derived Primary Medulloblastoma Cell Lines. In Brain Tumor Stem
1322 Cells, S. Singh, and C. Venugopal, eds. (Humana Press).
1323 https://doi.org/10.1007/978-1-4939-8805-1_3.
1324 9. Ivanov, D.P., Coyle, B., Walker, D.A., and Grabowska, A.M. (2016). In vitro
1325 models of medulloblastoma: Choosing the right tool for the job. Journal of
1326 Biotechnology *236*, 10-25. 10.1016/j.jbiotec.2016.07.028.
1327 10. Sanden, E., Dyberg, C., Krona, C., Gallo-Oller, G., Olsen, T.K., Enriquez Perez,
1328 J., Wickstrom, M., Estekizadeh, A., Kool, M., Visse, E., et al. (2017).
1329 Establishment and characterization of an orthotopic patient-derived Group 3
1330 medulloblastoma model for preclinical drug evaluation. Sci Rep *7*, 46366.
1331 10.1038/srep46366.
1332 11. Shu, Q., Wong, K.K., Su, J.M., Adesina, A.M., Yu, L.T., Tsang, Y.T., Antalffy,
1333 B.C., Baxter, P., Perlaky, L., Yang, J., et al. (2008). Direct orthotopic
1334 transplantation of fresh surgical specimen preserves CD133+ tumor cells in
1335 clinically relevant mouse models of medulloblastoma and glioma. Stem Cells
1336 *26*, 1414-1424. 10.1634/stemcells.2007-1009.
1337 12. Brabetz, S., Leary, S.E.S., Grobner, S.N., Nakamoto, M.W., Seker-Cin, H.,
1338 Girard, E.J., Cole, B., Strand, A.D., Bloom, K.L., Hovestadt, V., et al. (2018). A
1339 biobank of patient-derived pediatric brain tumor models. Nat Med *24*, 1752-
1340 1761. 10.1038/s41591-018-0207-3.
1341 13. Marino, S. (2005). Medulloblastoma: developmental mechanisms out of control.
1342 Trends Mol Med *11*, 17-22. 10.1016/j.molmed.2004.11.008.

14. Smith, K.S., Bihannic, L., Gudenas, B.L., Haldipur, P., Tao, R., Gao, Q., Li, Y., Aldinger, K.A., Iskusnykh, I.Y., Chizhikov, V.V., et al. (2022). Unified rhombic lip origins of group 3 and group 4 medulloblastoma. Nature *609*, 1012-1020. 10.1038/s41586-022-05208-9.
15. Hendrikse, L.D., Haldipur, P., Saulnier, O., Millman, J., Sjoboen, A.H., Erickson, A.W., Ong, W., Gordon, V., Coudiere-Morrison, L., Mercier, A.L., et al. (2022). Failure of human rhombic lip differentiation underlies medulloblastoma formation. Nature *609*, 1021-1028. 10.1038/s41586-022-05215-w.
16. Luo, Z., Xia, M., Shi, W., Zhao, C., Wang, J., Xin, D., Dong, X., Xiong, Y., Zhang, F., Berry, K., et al. (2022). Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature *612*, 787-794. 10.1038/s41586-022-05487-2.
17. Visvanathan, A., Saulnier, O., Chen, C., Haldipur, P., Orisme, W., Delaidelli, A., Shin, S., Millman, J., Bryant, A., Abeysundara, N., et al. (2024). Early rhombic lip Protogenin(+ve) stem cells in a human-specific neurovascular niche initiate and maintain group 3 medulloblastoma. Cell *187*, 4733-4750 e4726. 10.1016/j.cell.2024.06.011.
18. Bian, S., Repic, M., Guo, Z., Kavirayani, A., Burkard, T., Bagley, J.A., Krauditsch, C., and Knoblich, J.A. (2018). Genetically engineered cerebral organoids model brain tumor formation. Nat Methods *15*, 631-639. 10.1038/s41592-018-0070-7.
19. Choe, M.S., Kim, J.S., Yeo, H.C., Bae, C.M., Han, H.J., Baek, K., Chang, W., Lim, K.S., Yun, S.P., Shin, I.S., and Lee, M.Y. (2020). A simple metastatic brain cancer model using human embryonic stem cell-derived cerebral organoids. FASEB J *34*, 16464-16475. 10.1096/fj.202000372R.
20. Linkous, A., Balamatsias, D., Snuderl, M., Edwards, L., Miyaguchi, K., Milner, T., Reich, B., Cohen-Gould, L., Storaska, A., Nakayama, Y., et al. (2019). Modeling Patient-Derived Glioblastoma with Cerebral Organoids. Cell Rep *26*, 3203-3211 e3205. 10.1016/j.celrep.2019.02.063.
21. Vinel, C., Rosser, G., Guglielmi, L., Constantinou, M., Pomella, N., Zhang, X., Boot, J.R., Jones, T.A., Millner, T.O., Dumas, A.A., et al. (2021). Comparative epigenetic analysis of tumour initiating cells and syngeneic EPSC-derived neural stem cells in glioblastoma. Nat Commun *12*, 6130. 10.1038/s41467-021-26297-6.
22. Silva, T.P., Bekman, E.P., Fernandes, T.G., Vaz, S.H., Rodrigues, C.A.V., Diogo, M.M., Cabral, J.M.S., and Carmo-Fonseca, M. (2020). Maturation of Human Pluripotent Stem Cell-Derived Cerebellar Neurons in the Absence of Co-culture. Front Bioeng Biotechnol *8*, 70. 10.3389/fbioe.2020.00070.
23. Muguruma, K., Nishiyama, A., Kawakami, H., Hashimoto, K., and Sasai, Y. (2015). Self-organization of polarized cerebellar tissue in 3D culture of human pluripotent stem cells. Cell Rep *10*, 537-550. 10.1016/j.celrep.2014.12.051.
24. Atamian, A., Birtele, M., Hosseini, N., Nguyen, T., Seth, A., Del Dosso, A., Paul, S., Tedeschi, N., Taylor, R., Coba, M.P., et al. (2024). Human cerebellar organoids with functional Purkinje cells. Cell Stem Cell *31*, 39-51 e36. 10.1016/j.stem.2023.11.013.
25. Nayler, S., Agarwal, D., Curion, F., Bowden, R., and Becker, E.B.E. (2021). High-resolution transcriptional landscape of xeno-free human induced pluripotent stem cell-derived cerebellar organoids. Sci Rep *11*, 12959. 10.1038/s41598-021-91846-4.
26. Chen, Y., Bury, L.A., Chen, F., Aldinger, K.A., Miranda, H.C., and Wynshaw-Boris, A. (2023). Generation of advanced cerebellar organoids for

neurogenesis and neuronal network development. Hum Mol Genet *32*, 2832-2841. 10.1093/hmg/ddad110.

27. Ballabio, C., Anderle, M., Gianesello, M., Lago, C., Miele, E., Cardano, M., Aiello, G., Piazza, S., Caron, D., Gianno, F., et al. (2020). Modeling medulloblastoma in vivo and with human cerebellar organoids. Nat Commun *11*, 583. 10.1038/s41467-019-13989-3.
28. van Essen, M.J., Apsley, E.J., Riepsaame, J., Xu, R., Northcott, P.A., Cowley, S.A., Jacob, J., and Becker, E.B.E. (2024). PTCH1-mutant human cerebellar organoids exhibit altered neural development and recapitulate early medulloblastoma tumorigenesis. Dis Model Mech *17*. 10.1242/dmm.050323.
29. van Essen, M.J., Nicheperovich, A., Schuster-Bockler, B., Becker, E.B.E., and Jacob, J. (2025). Sonic hedgehog medulloblastoma cells in co-culture with cerebellar organoids converge towards in vivo malignant cell states. Neurooncol Adv *7*, vdae218. 10.1093/noajnl/vdae218.
30. Yang, J., Ryan, D.J., Wang, W., Tsang, J.C., Lan, G., Masaki, H., Gao, X., Antunes, L., Yu, Y., Zhu, Z., et al. (2017). Establishment of mouse expanded potential stem cells. Nature *550*, 393-397. 10.1038/nature24052.
31. Zhao, X., Liu, Z., Yu, L., Zhang, Y., Baxter, P., Voicu, H., Gurusiddappa, S., Luan, J., Su, J.M., Leung, H.C., and Li, X.N. (2012). Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma. Neuro Oncol *14*, 574-583. 10.1093/neuonc/nos061.
32. Gossen, M., Freundlieb, S., Bender, G., Müller, G., Hillen, W., and Bujard, H. (1995). Transcriptional activation by tetracyclines in mammalian cells. Science *268*, 1766-1769. 10.1126/science.7792603.
33. Hickmott, J.W., Chen, C.Y., Arenillas, D.J., Korecki, A.J., Lam, S.L., Molday, L.L., Bonaguro, R.J., Zhou, M., Chou, A.Y., Mathelier, A., et al. (2016). PAX6 MiniPromoters drive restricted expression from rAAV in the adult mouse retina. Mol Ther Methods Clin Dev *3*, 16051. 10.1038/mtm.2016.51.
34. Badodi, S., Dubuc, A., Zhang, X., Rosser, G., Da Cunha Jaeger, M., Kameda-Smith, M.M., Morrissy, A.S., Guilhamon, P., Suetterlin, P., Li, X.N., et al. (2017). Convergence of BMI1 and CHD7 on ERK Signaling in Medulloblastoma. Cell Rep *21*, 2772-2784. 10.1016/j.celrep.2017.11.021.
35. Badodi, S., Pomella, N., Zhang, X., Rosser, G., Whittingham, J., Niklison-Chirou, M.V., Lim, Y.M., Brandner, S., Morrison, G., Pollard, S.M., et al. (2021). Inositol treatment inhibits medulloblastoma through suppression of epigenetic-driven metabolic adaptation. Nat Commun *12*, 2148. 10.1038/s41467-021-22379-7.
36. Dobin, A., and Gingeras, T.R. (2015). Mapping RNA-seq Reads with STAR. Curr Protoc Bioinformatics *51*, 11 14 11-11 14 19. 10.1002/0471250953.bi1114s51.
37. Hao, Y., Hao, S., Andersen-Nissen, E., Mauck, W.M., Zheng, S., Butler, A., Lee, M.J., Wilk, A.J., Darby, C., Zager, M., et al. (2021). Integrated analysis of multimodal single-cell data. Cell *184*, 3573-3587.e3529. https://doi.org/10.1016/j.cell.2021.04.048.
38. Korsunsky, I., Millard, N., Fan, J., Slowikowski, K., Zhang, F., Wei, K., Baglaenko, Y., Brenner, M., Loh, P.R., and Raychaudhuri, S. (2019). Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods *16*, 1289-1296. 10.1038/s41592-019-0619-0.
39. Finak, G., McDavid, A., Yajima, M., Deng, J., Gersuk, V., Shalek, A.K., Slichter, C.K., Miller, H.W., McElrath, M.J., Prlic, M., et al. (2015). MAST: a flexible statistical framework for assessing transcriptional changes and characterizing

heterogeneity in single-cell RNA sequencing data. Genome Biology *16*, 278. 10.1186/s13059-015-0844-5.

40. Bhaduri, A., Andrews, M.G., Mancia Leon, W., Jung, D., Shin, D., Allen, D., Jung, D., Schmunk, G., Haeussler, M., Salma, J., et al. (2020). Cell stress in cortical organoids impairs molecular subtype specification. Nature *578*, 142-148. 10.1038/s41586-020-1962-0.
41. Kanton, S., Boyle, M.J., He, Z., Santel, M., Weigert, A., Sanchis-Calleja, F., Guijarro, P., Sidow, L., Fleck, J.S., Han, D., et al. (2019). Organoid single-cell genomic atlas uncovers human-specific features of brain development. Nature *574*, 418-422. 10.1038/s41586-019-1654-9.
42. Aldinger, K.A., Thomson, Z., Phelps, I.G., Haldipur, P., Deng, M., Timms, A.E., Hirano, M., Santpere, G., Roco, C., Rosenberg, A.B., et al. (2021). Spatial and cell type transcriptional landscape of human cerebellar development. Nat Neurosci *24*, 1163-1175. 10.1038/s41593-021-00872-y.
43. Zhong, S., Wang, M., Huang, L., Chen, Y., Ge, Y., Zhang, J., Shi, Y., Dong, H., Zhou, X., Wang, B., et al. (2023). Single-cell epigenomics and spatiotemporal transcriptomics reveal human cerebellar development. Nat Commun *14*, 7613. 10.1038/s41467-023-43568-6.
44. Sepp, M., Leiss, K., Murat, F., Okonechnikov, K., Joshi, P., Leushkin, E., Spanig, L., Mbengue, N., Schneider, C., Schmidt, J., et al. (2024). Cellular development and evolution of the mammalian cerebellum. Nature *625*, 788-796. 10.1038/s41586-023-06884-x.
45. Hovestadt, V., Smith, K.S., Bihannic, L., Filbin, M.G., Shaw, M.L., Baumgartner, A., DeWitt, J.C., Groves, A., Mayr, L., Weisman, H.R., et al. (2019). Resolving medulloblastoma cellular architecture by single-cell genomics. Nature *572*, 74-79. 10.1038/s41586-019-1434-6.
46. Venteicher, A.S., Tirosh, I., Hebert, C., Yizhak, K., Neftel, C., Filbin, M.G., Hovestadt, V., Escalante, L.E., Shaw, M.L., Rodman, C., et al. (2017). Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq. Science *355*, eaai8478. doi:10.1126/science.aai8478.
47. Vladoiu, M.C., El-Hamamy, I., Donovan, L.K., Farooq, H., Holgado, B.L., Sundaravadanam, Y., Ramaswamy, V., Hendrikse, L.D., Kumar, S., Mack, S.C., et al. (2019). Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature *572*, 67-73. 10.1038/s41586-019-1158-7.
48. Liberzon, A., Birger, C., Thorvaldsdottir, H., Ghandi, M., Mesirov, J.P., and Tamayo, P. (2015). The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst *1*, 417-425. 10.1016/j.cels.2015.12.004.
49. Korotkevich, G., Sukhov, V., Budin, N., Shpak, B., Artyomov, M.N., and Sergushichev, A. (2016). Fast gene set enrichment analysis. bioRxiv. 10.1101/060012.
50. Hanzelmann, S., Castelo, R., and Guinney, J. (2013). GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics *14*, 7. 10.1186/1471-2105-14-7.
51. La Manno, G., Soldatov, R., Zeisel, A., Braun, E., Hochgerner, H., Petukhov, V., Lidschreiber, K., Kastriti, M.E., Lönnerberg, P., Furlan, A., et al. (2018). RNA velocity of single cells. Nature *560*, 494-498. 10.1038/s41586-018-0414-6.
52. Bergen, V., Lange, M., Peidli, S., Wolf, F.A., and Theis, F.J. (2020). Generalizing RNA velocity to transient cell states through dynamical modeling. Nature Biotechnology *38*, 1408-1414. 10.1038/s41587-020-0591-3.
53. Cao, J., Spielmann, M., Qiu, X., Huang, X., Ibrahim, D.M., Hill, A.J., Zhang, F., Mundlos, S., Christiansen, L., Steemers, F.J., et al. (2019). The single-cell

transcriptional landscape of mammalian organogenesis. Nature *566*, 496-502. 10.1038/s41586-019-0969-x.

54. Linderman, G.C., Zhao, J., Roulis, M., Bielecki, P., Flavell, R.A., Nadler, B., and Kluger, Y. (2022). Zero-preserving imputation of single-cell RNA-seq data. Nat Commun *13*, 192. 10.1038/s41467-021-27729-z.
55. Efremova, M., Vento-Tormo, M., Teichmann, S.A., and Vento-Tormo, R. (2020). CellPhoneDB: inferring cell-cell communication from combined expression of multi-subunit ligand-receptor complexes. Nat Protoc *15*, 1484-1506. 10.1038/s41596-020-0292-x.
56. Pidsley, R., Wong, C.C.Y., Volta, M., Lunnon, K., Mill, J., and Schalkwyk, L.C. (2013). A data-driven approach to preprocessing Illumina 450K methylation array data. BMC Genomics *14*. https://doi.org/10.1186/1471-2164-14-293.
57. Steg, L.C., Shireby, G.L., Imm, J., Davies, J.P., Franklin, A., Flynn, R., Namboori, S.C., Bhinge, A., Jeffries, A.R., Burrage, J., et al. (2021). Novel epigenetic clock for fetal brain development predicts prenatal age for cellular stem cell models and derived neurons. Mol Brain *14*, 98. 10.1186/s13041-021-00810-w.
58. Peters, T.J., Buckley, M.J., Statham, A.L., Pidsley, R., Samaras, K., Lord, R.V., Clark, S.J., and Molloy, P.L. (2015). De novo identification of differentially methylated regions in the human genome. Epigenetics & Chromatin *8*. https://doi.org/10.1186/1756-8935-8-6.
59. Hovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P.A., Fischer, R., Cavalli, F.M., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013). Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol *125*, 913-916. 10.1007/s00401-013-1126-5.
60. Kolberg, L., Raudvere, U., Kuzmin, I., Adler, P., Vilo, J., and Peterson, H. (2023). g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res *51*, W207-W212. 10.1093/nar/gkad347.
61. Shannon, P., Markiel, A., Ozier, O., Baliga, N.S., Wang, J.T., Ramage, D., Amin, N., Schwikowski, B., and Ideker, T. (2003). Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res *13*, 2498-2504. 10.1101/gr.1239303.
62. Frantz GD, W.J., Levin ME, McConnell SK (1994). Otx1 and Otx2 define layers and regions in developing cerebral cortex and cerebellum. J Neurosci *14*, 5725-5740. 10.1523/JNEUROSCI.14-10-05725.1994.
63. Badodi, S., and Marino, S. (2022). Epigenetic mechanisms in paediatric brain tumours: regulators lose control. Biochem Soc Trans *50*, 167-185. https://doi.org/10.1042/BST20201227.
64. Zagozewski, J., Shahriary, G.M., Morrison, L.C., Saulnier, O., Stromecki, M., Fresnoza, A., Palidwor, G., Porter, C.J., Forget, A., Ayrault, O., et al. (2020). An OTX2-PAX3 signaling axis regulates Group 3 medulloblastoma cell fate. Nat Commun *11*, 3627. 10.1038/s41467-020-17357-4.
65. Jones, D.T., Jager, N., Kool, M., Zichner, T., Hutter, B., Sultan, M., Cho, Y.J., Pugh, T.J., Hovestadt, V., Stutz, A.M., et al. (2012). Dissecting the genomic complexity underlying medulloblastoma. Nature *488*, 100-105. 10.1038/nature11284.
66. Kahn, S.A., Wang, X., Nitta, R.T., Gholamin, S., Theruvath, J., Hutter, G., Azad, T.D., Wadi, L., Bolin, S., Ramaswamy, V., et al. (2018). Notch1 regulates the

initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nat Commun *9*, 4121. 10.1038/s41467-018-06564-9.

67. Rattenberry, W., McDonough, C.H., Burger, P.C., and Cohen, K.J. (2011). Medulloblastoma with myogenic differentiation: long-term survival in a patient treated with aggressive combination therapy and autologous stem cell transplantation. J Neurooncol *105*, 659-662. 10.1007/s11060-011-0626-1.
68. Crawford, J.R., and Levy, M.L. (2015). Medulloblastoma with myogenic differentiation: a rare medulloblastoma variant in a young child. BMJ Case Rep *2015*. 10.1136/bcr-2015-212322.
69. van Bree, N.F.H.N., and Wilhelm, M. (2022). The Tumor Microenvironment of Medulloblastoma: An Intricate Multicellular Network with Therapeutic Potential. Cancers *14*. 10.3390/cancers14205009.
70. Fan, Q., Wang, H., Gu, T., Liu, H., Deng, P., Li, B., Yang, H., Mao, Y., and Shao, Z. (2024). Modeling the precise interaction of glioblastoma with human brain region-specific organoids. iScience *27*, 109111. 10.1016/j.isci.2024.109111.
71. Prior, V.G., Maksour, S., Miellet, S., Hulme, A.J., Chen, Y., Mirzaei, M., Wu, Y., Dottori, M., and O'Neill, G.M. (2024). Parsing the effect of co-culture with brain organoids on Diffuse Intrinsic Pontine Glioma (DIPG) using quantitative proteomics. Int J Biochem Cell Biol *174*, 106617. 10.1016/j.biocel.2024.106617.
72. Badodi, S., Pomella, N., Lim, Y.M., Brandner, S., Morrison, G., Pollard, S.M., Zhang, X., Zabet, N.R., and Marino, S. (2022). Combination of BMI1 and MAPK/ERK inhibitors is effective in medulloblastoma. Neuro Oncol. 10.1093/neuonc/noac052.
73. Northcott, P.A., Shih, D.J., Peacock, J., Garzia, L., Morrissy, A.S., Zichner, T., Stutz, A.M., Korshunov, A., Reimand, J., Schumacher, S.E., et al. (2012). Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature *488*, 49-56. 10.1038/nature11327.
74. Kawauchi, D., Ogg, R.J., Liu, L., Shih, D.J.H., Finkelstein, D., Murphy, B.L., Rehg, J.E., Korshunov, A., Calabrese, C., Zindy, F., et al. (2017). Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. Oncogene *36*, 5231-5242. 10.1038/onc.2017.110.
75. Pei, Y., Moore, C.E., Wang, J., Tewari, A.K., Eroshkin, A., Cho, Y.J., Witt, H., Korshunov, A., Read, T.A., Sun, J.L., et al. (2012). An animal model of MYC-driven medulloblastoma. Cancer Cell *21*, 155-167. 10.1016/j.ccr.2011.12.021.
76. Williamson, D., Schwalbe, E.C., Hicks, D., Aldinger, K.A., Lindsey, J.C., Crosier, S., Richardson, S., Goddard, J., Hill, R.M., Castle, J., et al. (2022). Medulloblastoma group 3 and 4 tumors comprise a clinically and biologically significant expression continuum reflecting human cerebellar development. Cell Rep *40*, 111162. 10.1016/j.celrep.2022.111162.
77. Pine, A.R., Cirigliano, S.M., Nicholson, J.G., Hu, Y., Linkous, A., Miyaguchi, K., Edwards, L., Singhania, R., Schwartz, T.H., Ramakrishna, R., et al. (2020). Tumor Microenvironment Is Critical for the Maintenance of Cellular States Found in Primary Glioblastomas. Cancer Discov *10*, 964-979. 10.1158/2159-8290.CD-20-0057.
78. Yang, J., Kim, S.K., Wang, K.C., Kim, K.H., Park, S.H., and Phi, J.H. (2021). A boy with a congenital cerebellar mass. Childs Nerv Syst *37*, 983-987. 10.1007/s00381-020-04767-4.
79. Moradi, B., Hamidian, Y., Soltanghoraee, H., and Katouli, F.S. (2023). Prenatally detected congenital medulloblastoma. J Clin Ultrasound *51*, 432-435. 10.1002/jcu.23278.

80. Gupta, K., Jogunoori, S., Satapathy, A., Salunke, P., Kumar, N., Radotra, B.D., and Vasishta, R.K. (2018). Medulloblastoma with myogenic and/or melanotic differentiation does not align immunohistochemically with the genetically defined molecular subgroups. Hum Pathol *75*, 26-33. 10.1016/j.humpath.2018.01.014.
81. Nicholson, J.G., Cirigliano, S., Singhania, R., Haywood, C., Shahidi Dadras, M., Yoshimura, M., Vanderbilt, D., Liechty, B., and Fine, H.A. (2024). Chronic hypoxia remodels the tumor microenvironment to support glioma stem cell growth. Acta Neuropathol Commun *12*, 46. 10.1186/s40478-024-01755-6.
82. Qu, F., Brough, S.C., Michno, W., Madubata, C.J., Hartmann, G.G., Puno, A., Drainas, A.P., Bhattacharya, D., Tomasich, E., Lee, M.C., et al. (2023). Crosstalk between small-cell lung cancer cells and astrocytes mimics brain development to promote brain metastasis. Nat Cell Biol *25*, 1506-1519. 10.1038/s41556-023-01241-6.
83. Northcott, P.A., Korshunov, A., Witt, H., Hielscher, T., Eberhart, C.G., Mack, S., Bouffet, E., Clifford, S.C., Hawkins, C.E., French, P., et al. (2011). Medulloblastoma comprises four distinct molecular variants. J Clin Oncol *29*, 1408-1414. 10.1200/JCO.2009.27.4324.
84. Hayden Gephart, M.G., Su, Y.S., Bandara, S., Tsai, F.C., Hong, J., Conley, N., Rayburn, H., Milenkovic, L., Meyer, T., and Scott, M.P. (2013). Neuropilin-2 contributes to tumorigenicity in a mouse model of Hedgehog pathway medulloblastoma. J Neurooncol *115*, 161-168. 10.1007/s11060-013-1216-1.
85. Trombetta-Lima, M., Rosa-Fernandes, L., Angeli, C.B., Moretti, I.F., Franco, Y.M., Mousessian, A.S., Wakamatsu, A., Lerario, A.M., Oba-Shinjo, S.M., Pasqualucci, C.A., et al. (2021). Extracellular Matrix Proteome Remodeling in Human Glioblastoma and Medulloblastoma. J Proteome Res *20*, 4693-4707. 10.1021/acs.jproteome.1c00251.
86. Vestal, K.A., Kattamuri, C., Koyiloth, M., Ongaro, L., Howard, J.A., Deaton, A.M., Ticau, S., Dubey, A., Bernard, D.J., and Thompson, T.B. (2024). Activin E is a transforming growth factor beta ligand that signals specifically through activin receptor-like kinase 7. Biochem J *481*, 547-564. 10.1042/BCJ20230404.
87. Liu, H., Sun, Y., O'Brien, J.A., Franco-Barraza, J., Qi, X., Yuan, H., Jin, W., Zhang, J., Gu, C., Zhao, Z., et al. (2020). Necroptotic astrocytes contribute to maintaining stemness of disseminated medulloblastoma through CCL2 secretion. Neuro Oncol *22*, 625-638. 10.1093/neuonc/noz214.
88. Liang, K.H., Chang, C.C., Wu, K.S., Yu, A.L., Sung, S.Y., Lee, Y.Y., Liang, M.L., Chen, H.H., Fen, J.J., Chao, M.E., et al. (2021). Notch signaling and natural killer cell infiltration in tumor tissues underlie medulloblastoma prognosis. Sci Rep *11*, 23282. 10.1038/s41598-021-02651-y.

Supplementary Figures and Legends


A
Y
SB
FGF2
Insulin
FGF19
SDF1
Day 7
Day 14
Day 21
Day 28
Day 35
B
Average Diameter (µm)
Days of differentiation
CbO_19
CbO_61
Relative Growth
ns
Day 14 vs Day 7
Day 35 vs Day 14
C Stemness
Relative Expression
NANOG
D Cerebellar Morphogenesis Markers
NESTIN
SOX1
EN2
OTX2
E GABAergic Markers
KIRREL2
OLIG2
SKOR2
F Glutamatergic Markers
PAX6
ATOH1
BARHL1
EOMES
CbO_19
CbO_61
Days in culture
G
CbO Age
D7
D35
D49
H
UMAP.1
UMAP.2
Glutamatergic Progenitors
Glutamatergic Neurons
GABA Progenitors
Glial Progenitors
Low Q
I
MKI67
TOP2A
UBE2C
NES
SOX2
SFRP1
LHX5-AS1
OTX2
PAX6
VSNL1
NEUROD4
NEUROG1
ONECUT2
GBX2
PAX2
PAX5
NRP2
VCAN
PKDCC
PLP1
SOX9
S100B
FOXD3-AS1
Glut. Prog.
Glut. Neurons
GABA Prog.
Glial Prog.
Low Q
Percent Expressed
Average Expression
J
K
D35
D49
L
Zhong et al
Aldinger et al
Luo et al
Sepp et al
class
Pearson Correlation
Class
Progenitors
Astroglial
Neu.Prog
UBC
Granule
Interneuron
Purkinje
Neuron
OPC/oligo
ChP/Ependymal
Meninges/Vasc
other

1645

1646 ***Supplementary Figure 1. CbO displays sustained growth and maturation.***

1647 A. Schematic of protocol used to generate and differentiate CbO, (see Methods,
1648 Y: Y-27632 Dihydrochloride and SB: SB431542) and representative brightfield
1649 pictures of CbO_61 upon 7, 14, 21, 28 and 35 days of differentiation. Scale
1650 bar = 1000 µm.

1651 B. Diameter analysis of CbO obtained from two independent EPSC lines
1652 (CbO_19 and CbO_61) across 35 days of maturation (left) and analysis of
1653 relative growth comparing Day 14 to Day 7 or Day 35. Asterisks indicate p-
1654 values between given time point and Day 7, two-way ANOVA, ****p<0.0001,
1655 ns: not significant. n = 10 independent CbO average diameters per timepoint.

1656 C. qPCR analysis showing quantification of *NANOG* expression in CbO_19 and
1657 CbO_61 across 35 days of maturation.

1658 D. qPCR analysis showing quantification of *NESTIN, SOX1, EN2* and *OTX2*
1659 expression in CbO_19 and CbO_61 across 35 days of maturation.

1660 E. qPCR analysis showing quantification of *KIRREL2* and *SKOR2* expression in
1661 CbO_19 and CbO_61 across 35 days of maturation.

1662 F. qPCR analysis showing quantification of *PAX6, ATOH1, BARHL1* and
1663 *EOMES* expression in CbO_19 and CbO_61 across 35 days of maturation.

1664 Relative RNA level was calculated as 2^(-dCT) values normalised to EPSC
1665 baseline (Day 0). All graphs report mean ± SEM, Welch's unpaired t-test,
1666 *p<0.05, **p<0.01, ***p<0.001. non-significant comparisons are not shown.
1667 Data points show average values for n = 3 independent batches of CbO per
1668 timepoint.

1669 G. UMAP plot of scRNA-Seq data from all CbO samples submitted at Day 7
1670 (CbO_19 and CbO_61), 35 (CbO_19 and CbO_61)and 49 (CbO_61) of
1671 differentiation coloured by timepoint.

1672 H. UMAP plot of scRNA-Seq data from CbO at Day 7 of differentiation coloured
1673 by annotated Louvain clusters.

1674 I. Dot plot showing key marker genes used to identify major cell types in CbO at
1675 Day 7 of differentiation.

1676 J. UMAP plot of scRNA-Seq data from CbO samples at Day 35/49 of
1677 differentiation, identifying 17 clusters and sub clustering of cluster 7 into 7_0
1678 and 7_1. Low quality hypoxic clusters 13 and 14 not shown.

1679 K. UMAP plot of scRNA-Seq data shown in K, split by Day 35 (upper) and Day
1680 49 (lower) timepoints.

1681 L. Heatmap showing correlation of CbO D35/49 clusters identified in K to
1682 clusters annotated by cell type of four independent scRNA-seq datasets of the
1683 human developing foetal cerebellum[1-4].

1684


A
19 PCW
20 PCW
23 PCW
25 PCW
27 PCW
28 PCW
29 PCW
30 PCW
34 PCW
35 PCW
36 PCW
37 PCW
10 mm
5 mm
B
C
Metabolism
Vescicle Transport
Embryogenesis
Proliferation
Tissue Development
Signal Transduction
Differentiation
Neuron Projection
Homeostasis
Cell Motility
Glycolysis
Nervous System Development
Transcription
Transcriptional Regulation
Hormone Secretion
Catalitic Activity
Methylation Z-score
-4
4
Clusters: 1 2 3 4 5
D
Hyper_DOWN
Clusters 4 & 5
Hypo_UP
Clusters 1 & 2
36
24
0
0
13
32
0
9
511
15
10
62
35
10
13
Biological Process and Molecular Functions
Common Hypo_UP and Clusters 3&4
Synapse Dendrite Neurons
FDR
0.04
1x10-6
Common Hyper_DOWN and Clusters 1&2
Tissue Morphogenesis
Collagen/ECM
Cell Adhesion
Proliferation Biosynthetic Regulation
Phosphorus Metabolism
Receptors Signalling
FDR
0.05
1x10-4

1687 ***Supplementary Figure 2. Staging development of CbO comparatively to human***
1688 ***cerebellum reveals conserved epigenetically regulated genes and pathways.***

1689 A. H&E staining of FFPE samples from human foetal cerebellum. Non-cerebellar
1690 tissue excluded from the microdissection is circled. Developmental stage in
1691 post-conception weeks (PCW) and scale bars are shown.

1692 B. Heatmap showing k-means clustering (n=5) of significant variable methylated
1693 genes across human foetal cerebellar development from Carnegie stage (cs)
1694 22 to 37 post-conception weeks (pcw). Z-scores for average beta values of
1695 probes contained within each gene are plotted.

1696 C. Bubble plot showing top 100 significant (adjusted p-value < 0.05) GO
1697 Biological Processes and Molecular Functions of genes from 5 clusters shown
1698 in B taken for pathway analysis in g:Profiler. Bubbles are coloured based on
1699 each clusters and size is proportional to number of genes in specific GO term.

1700 D. Venn diagram showing integrative analysis of significant GOs in most variable
1701 methylated (Figure 2D) and concordant (Figure 2E) genes (left panel).
1702 Bubbles plot showing common pathways between genes
1703 upregulated/hypomethylated and in clusters 3 and 4 (middle panel) or genes
1704 downregulated/hypermethylated and in clusters 1 and 2 (left panel). Bubbles
1705 are coloured based on FDR and size is proportional to number of genes of
1706 specific GO term.

1707

1708


A
cs22
cs23
9pcw
10pcw
11pcw
12pcw
13pcw
14pcw
15pcw
16pcw
17pcw
19pcw
20pcw
23pcw
25pcw
26pcw
28pcw
29pcw
30pcw
34pcw
35pcw
36pcw
37pcw
Pearson Correlation
1
-0.5
B
R-squared: 0.8
Epigenetic Age (days post conception)
Chronological Age (days in culture)
Type of Epi-Age estimates
Cb0_19 fitted by FBC
Cb0_61 fitted by FBC
C
EOMES Expression
Score
UMAP.2
UMAP.1
D
E
Pseudotime
F
G3 Trajectory
G4 Trajectory
Pseudotime
Expresion z-score
PAX3
HES1
SFRP2
RSPO2
OTX2
NID2
LMX1A
UBXN4
SSX2IP
GNB3
NEUROG1
CRX
CDHR1
EOMES
PCBP4
GSE1
AMER2
MEF2C
ONECUT1
PTH2
NXPH1
SEMA3E
CASZ1
TMX1
INHBB

1711 ***Supplementary Figure 3. CbO clusters harbouring MB cell-of-origin are***
1712 ***enriched for distinct G3 and G4 MB associated gene signatures.***

1713 A. Heatmap showing correlation of methylation status of top 1% age-dependent
1714 probes between human developing cerebellum samples, demonstrating a
1715 linear correlation through development.

1716 B. Correlation plot between days of maturation of CbO_19 and CbO_61
1717 (chronological age) and the modelled epigenetic ages from the foetal brain
1718 clock[5].

1719 C. Uniform Manifold Approximation and projection (UMAP) of Day 35/49 CbO
1720 showing alra imputed expression score for *EOMES.*

1721 D. Day 35/49 CbO UMAP with RNA velocity streams shown, calculated in
1722 velocyto and scVelo.

1723 E. Pseudotime analysis of Day 35/49 CbO UMAP calculated in Monocle3, with
1724 cycling progenitors cluster (see Figure 1G) selected as the root of
1725 pseudotime.

1726 F. Plots of z-scored gene expression through pseudotime within G3 and G4
1727 trajectories defined in Figure 3K.

1728

1729


A
Relative RNA level
1.5
1.0
0.5
0.0
ns
NANOG
GATA6
MYC
EPSC19
pPAX6; MYC-GFP
pEOMES; MYC-GFP
B
pPAX6; MYC-GFP +DOX
pPAX6 +DOX
pPAX6; MYC-GFP no DOX
pEOMES; MYC-GFP +DOX
pEOMES +DOX
pEOMES; MYC-GFP no DOX
D39
D46
D63
C
UMAP.1
UMAP.2
pEOMES.CTRL
pEOMES-MYCOE
pPAX6.CTRL
pPAX6-MYCOE
D
Cyc_progenitors
Progenitors
Roof_Plate
Berg_Glia
NSCs
early_RL/NSC
glut_progenitors
GN/UBC_progs
GN/UBC
GPC
matCN1
matCN2
Purkinje
Ependymal/ChP
Meninges
MYCOE
E
G1
G2/M
S
F
G3 Signature
3.5
1
G
Hallmark MYC Targets
p.adj=2.42x10-22
NES=3.63
enrichment score
rank
H
Synapse Assembly
p.adj=2.20x10-7
NES= -2.35
Regulation Axonogenesis
p.adj=6.73x10-7
NES= -2.36
Synaptic Membrane Adhesion
p.adj=1.17x10-5
NES= -2.38
I
beta value
1
0.5
0
CbO-CTRL
CbO-MYCOE
Group3
Group4
SHH
WNT
J
Group3
Group4
Pearson Correlation
0.06
0.04
0.02
0
-0.02
pEOMES-MYCOE
pPAX6-MYCOE
pEOMES.CTRL
pPAX6.CTRL

1732 ***Supplementary Figure 4. Cerebellar organoid editing strategy displays***
1733 ***specificity to medulloblastoma lineages-of-origin and similar***
1734 ***methylation profiles***

1735 A. qPCR data of naïve expanded potential stem cells (EPSC19) and EPSC19
1736 infected with *pPAX6;MYC-GFP* or *pEOMES;MYC-GFP* editing constructs
1737 outlined in Figure 4A for pluripotency (*NANOG)* and differentiation (*GATA6)*
1738 markers as well as c-*MYC.* Relative RNA level signifies dCT values
1739 expressed relative to naïve EPSC19 (2^-ddCT). ns = not significant, one-way
1740 ANOVA. n = 3 technical replicates.

1741 B. Representative images of CbO19 at Day 36, 46 and 63 of culture infected with
1742 different combinations of *pPAX6, pEOMES* or *MYC-GFP* editing constructs
1743 (refer to Figure 4A), with or without the addition of doxycycline (DOX) to
1744 organoid media from Day 35 of culture.

1745 C. UMAP plot of scRNA-Seq data from D63 *pEOMES;MYC-GFP, pPAX6;MYC-*
1746 *GFP* (*pEOMES*-MYC^{OE}, *pPAX6*-MYC^{OE}) and control (CTRL) CbOs coloured
1747 by Louvain clusters (left). Barplot showing the relative proportion of cells
1748 clusters in each sample (right).

1749 D. Barplot showing the relative proportion of cell types in each cluster in **C**
1750 (labels transferred from D35/49 control CbOs (Figure 1G).

1751 E. UMAP plot shown in C, coloured by cell cycle phase.

1752 F. UMAP plot shown in C, showing Group 3 MB signature score[6].

1753 G. Gene set enrichment plot of the HALLMARKs MYC TARGETS V1 gene set in
1754 the MYC^{OE} cluster markers (Figure 4C), NES=3.63, padj=2.24E-22.

1755 H. Gene set enrichment plot showing depletion of gene sets associated with
1756 neural differentiation in MYC^{OE} cells relative to D35/49 G3/4 lineage-of-origin
1757 cells.

1758 I. Clustered heatmap of medulloblastoma (MB) samples taken from Cavalli et
1759 al.[7] and edited CbO samples based on their beta values of probes shown to
1760 delineate MB subgroups[8].

1761 J. Clustered heatmap of edited CbO sample correlation to group 3 and group 4
1762 MBs from the Cavalli et al. dataset[7] on the beta values of differentially
1763 methylated probes between *MYC* overexpressing (*pEOMES*-MYC^{OE}, *pPAX6*-
1764 MYC^{OE}*)* and control medulloblastoma lineage-of-origin samples
1765 (*pEOMES.*ctrl, *pPAX6.*ctrl).

1766

1767

1768


CbO-G3/G4 MB
CbO-Med211FH
CbO-CHLA-01-Med
GFP+ MB cells Nuclei
A
B
C
D
E
F
G
H&E
H&E
UMAP.2
UMAP.1
CbO
CbO-CHLA-01-Med.1
CbO-CHLA-01-Med.2
CbO-Med211FH_invitro
CbO-Med211FH_PDX
NSC73_5
H
Copy Number Variations
Expression
Med211
CHLA.01
CbO
CbO
CbO-MB co-cultures
Genomic Region
I
SOX2
SOX9
DCX
DLX1
DLX2
SIX3
APOE
HMGA1
MYC
YBX3
TRAP1
NEUROD1
BCAT1
CbO
NSC73_5
CHLA-01-Med
Med211 FH
Percent Expressed
25
50
75
Average Expression
1
0
-1
J
Prediction Score G3
1
0.5
0.25
Prediction Score G4
0.8
0.4
0
K
class
cluster_0
cluster_3
cluster_1
cluster_7
cluster_2
cluster_5
cluster_8
cluster_4
cluster_6
MB.cell.line
MB Cells
CHLA-01-Med
Med211FH
Pearson Correlation
0.4
0
-0.4
Class
Astroglial
ChP/Ependymal
Granule
Interneuron
Meninges/Vasc
Neu.Prog
Neuron
OPC/oligo
other
Progenitors
Purkinje
UBC

1771 ***Supplementary Figure 5. Medulloblastoma (MB) cells display the morphology***
1772 ***of human MB upon co-culture with cerebellar organoids (CbO) and retain their***
1773 ***genetic features.***

1774 A. Representative immunofluorescence staining of GFP$^+$ ICb1299 G3/4 MB cells
1775 upon fourteen days of co-culture with CbO_61, scale bar = 100 µm.

1776 B. Representative immunofluorescence staining of GFP$^+$ CHLA-01R-Med
1777 recurrent G3/4 MB cells upon fourteen days of co-culture with CbO_61, scale
1778 bar = 100 µm.

1779 C. Representative immunofluorescence staining of GFP$^+$ Med211FH cells upon
1780 fourteen days of co-culture with CbO_61, scale bar = 50 µm.

1781 D. H&E staining of CbO-Med211FH co-cultures upon 14 days of co-culture with
1782 MB cells, scale bars = 50 µm.

1783 E. H&E staining of CbO-CHLA-01-Med co-cultures upon 14 days of co-culture
1784 with MB cells, scale bars = 100 µm.

1785 F. H&E staining of CbO-Med211FH co-cultures upon 14 days of co-culture with
1786 MB cells, scale bars = 100 µm.

1787 G. UMAP plot of scRNA-Seq data from D49 control CbO_61, CbO-Med211-FH,
1788 CbO-CHLA-01-Med and control CbO-NSC73.5 co-cultures, coloured by
1789 sample.

1790 H. Hierarchical clustering of inferred copy number profiles separates co-cultured
1791 CHLA-01-Med (suede) and CbO-Med211-FH (yellow) from CbO (cyan) cells.

1792 I. Dot plot showing key marker genes that distinguish co-culture NSC73_5,
1793 CHLA-01-Med and CbO-Med211-FH cell populations from CbO.

1794 J. UMAP plot of scRNA-Seq data from MB cells only from D49 CbO-Med211-FH
1795 and CbO-CHLA-01-Med CbO-MB co-cultures, coloured by label transfer
1796 scores for Group3 (top), Group 4 (bottom).

1797 K. Heatmap showing correlation of co-cultured Med211-FH and CHLA-01-Med
1798 scRNA-Seq clusters to reference cell type from four independent scRNA-seq
1799 datasets of the human developing foetal cerebellum[1-4].

1800

1801

1802


A
UMAP.1
UMAP.2
B
Model
Control
CbO-NSC
CbO-CHLA-01-Med
CbO-Med211FH
Cell Type
Cyc.Progenitors
Progenitors
Roof.Plate
Berg.Glia
NSCs
early.RL/NSCs
Glut.Progenitors
GN/UBC.Progs
GN/UBC
GPC
matCN1
matCN2
Purkinje
Ependymal/ChP
Meninges
CHLA-01-Med
Med211FH
NSC73.5
C
Joint Cell Type
Cyc.Progs/NSCs
Progenitors
Ependymal/ChP
Meninges
GPC1
GPC2
MatCN
CHLA-01-Med
Med211FH
NSC73.5
Control
CbO-NSC
CbO-CHLA-01-Med
CbO-Med211FH
D
Control
CbO-NSC
CbO-CHLA-01-Med
CbO-Med211FH
E
GFP+MB cells
TUBIII cCASP3
MAP2
F
RL Interactions
Cyc.Progs/NSCs
Progenitors
GPC1
GPC2
MatCN
Ependymal/ChP
Meninges
CHLA-01-Med
Med211FH
NSC73.5
n
G
Cyc.Progs/NSCs
Progenitors
GPC1
GPC2
Ependymal/ChP
Meninges
-Log10FDR
Log2 FC (sc-RNAseq)
H
Downregulated Pathways
Upregulated Pathways
Neurogenesis
Apoptosis
Homeostasis
Cilium Assembly
Transcription
Respiration
Cytoskeletal Transport
CNS Development
Vesicle Transport
Energy Metabolism
rRNA processing
Protein Modification
I
BMI1i/MAPKi
IP6
Day 49
53
Viable cells
CbO-MB:
GFP+ MB cells
GFP- CbO cells
BMI1i (μM)
MAPKi (nM)
IP6 (μM)
J
Viable cells
BMI1i/MAPKi
IP6

1805 ***Supplementary Figure 6. Co-culture with medulloblastoma cells modulates***
1806 ***transcriptional profiles of specific cerebellar organoid lineages.***

1807 A. UMAP plot of scRNA-Seq data from D49 control CbO_61, CbO-Med211-FH,
1808 CbO-CHLA-01-Med and control CbO-NSC73_5 co-cultures, coloured by
1809 Louvain clusters.

1810 B. Barplot showing proportion of each cluster made up of cells from CbO_61
1811 control, CbO-Med211-FH, CbO-CHLA-01-Med or CbO-NSC73_5 co-culture
1812 samples (left). Barplot showing proportion of each cluster made up of different
1813 cell types from CbO_61 control, CbO-Med211-FH, CbO-CHLA-01-Med or
1814 CbO-NSC73_5 co-culture samples (right). For CbO clusters cell labels were
1815 computationally transferred from D35/49 controls (Fig 1G).

1816 C. Barplot showing proportion of samples in A, B made up by the joint cell type
1817 labels.

1818 D. Uniform manifold approximation and projections (UMAPs) plot of scRNA-Seq
1819 data from D49 control CbO, CbO-Med211-FH, CbO-CHLA-01-Med and
1820 control CbO-NSC73_5 co-cultures. Cells are coloured by their assigned cell
1821 type and UMAPs are split according to experimental model.

1822 E. Immunohistochemistry images of cerebellar organoids co-cultured with
1823 NSC73.5 cells for 14 days. Upper panel: GFP (green), cCASP3 (red) and
1824 TubIII (white); Lower panel: GFP (green), cCASP3 (red) and MAP2 (white).
1825 Scale bars = 10 µm.

1826 F. Heatmap showing the total number of predicted significant receptor-ligand
1827 interactions (regardless of directionality) between co-cultured CbO-Med211-
1828 FH, CbO-CHLA-01-Med and control CbO-NSC73_5 cells and CbO_61 cell
1829 populations.

1830 G. Volcano plots showing significant differentially expressed genes (DEGs) upon
1831 MB cells co-culture in indicated CbO_61 cell populations. Red and blue dots
1832 represent significantly upregulated and downregulated genes respectively.

1833 H. Bubble plot showing top 100 significant (adjusted p-value < 0.05) GO
1834 Biological Processes and Molecular Functions of up- (red) and down- (blue)
1835 regulated genes from 6 volcano plots shown in G taken for pathway analysis
1836 in g:Profiler. Bubbles are coloured based on each cell population and size is
1837 proportional to number of genes in specific GO term.

1838 I. Schematic of CbO-CHLA-01-Med treatment with tables reporting the
1839 concentrations of PTC209 (BMI1i), PD329501 (MAPKi) and IP6 used.

1840 J. Viability assays of GFP^+ MB cells (green) and GFP^- CbO cells (pink) in CbO-
1841 MB upon 4 days of treatment with increasing concentrations of BMI1 and
1842 MAPK inhibitors (left) or IP6 (right) as shown in Figure 5H and 5I respectively.
1843 All graphs report mean ± SEM, number of independent CbO analyzed is
1844 reported in each graph, one-way ANOVA *p<0.05, ***p<0.001,
1845 ****p<0.0001, ns = not significant.

1846

References

1. Zhong, S., Wang, M., Huang, L., Chen, Y., Ge, Y., Zhang, J., Shi, Y., Dong, H., Zhou, X., Wang, B., et al. (2023). Single-cell epigenomics and spatiotemporal transcriptomics reveal human cerebellar development. Nat Commun *14*, 7613. 10.1038/s41467-023-43568-6.
2. Aldinger, K.A., Thomson, Z., Phelps, I.G., Haldipur, P., Deng, M., Timms, A.E., Hirano, M., Santpere, G., Roco, C., Rosenberg, A.B., et al. (2021). Spatial and cell type transcriptional landscape of human cerebellar development. Nat Neurosci *24*, 1163-1175. 10.1038/s41593-021-00872-y.
3. Luo, Z., Xia, M., Shi, W., Zhao, C., Wang, J., Xin, D., Dong, X., Xiong, Y., Zhang, F., Berry, K., et al. (2022). Human fetal cerebellar cell atlas informs medulloblastoma origin and oncogenesis. Nature *612*, 787-794. 10.1038/s41586-022-05487-2.
4. Sepp, M., Leiss, K., Murat, F., Okonechnikov, K., Joshi, P., Leushkin, E., Spanig, L., Mbengue, N., Schneider, C., Schmidt, J., et al. (2024). Cellular development and evolution of the mammalian cerebellum. Nature *625*, 788-796. 10.1038/s41586-023-06884-x.
5. Steg, L.C., Shireby, G.L., Imm, J., Davies, J.P., Franklin, A., Flynn, R., Namboori, S.C., Bhinge, A., Jeffries, A.R., Burrage, J., et al. (2021). Novel epigenetic clock for fetal brain development predicts prenatal age for cellular stem cell models and derived neurons. Mol Brain *14*, 98. 10.1186/s13041-021-00810-w.
6. Vladoiu, M.C., El-Hamamy, I., Donovan, L.K., Farooq, H., Holgado, B.L., Sundaravadanam, Y., Ramaswamy, V., Hendrikse, L.D., Kumar, S., Mack, S.C., et al. (2019). Childhood cerebellar tumours mirror conserved fetal transcriptional programs. Nature *572*, 67-73. 10.1038/s41586-019-1158-7.
7. Cavalli, F.M.G., Remke, M., Rampasek, L., Peacock, J., Shih, D.J.H., Luu, B., Garzia, L., Torchia, J., Nor, C., Morrissy, A.S., et al. (2017). Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell *31*, 737-754 e736. 10.1016/j.ccell.2017.05.005.
8. Hovestadt, V., Remke, M., Kool, M., Pietsch, T., Northcott, P.A., Fischer, R., Cavalli, F.M., Ramaswamy, V., Zapatka, M., Reifenberger, G., et al. (2013). Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol *125*, 913-916. 10.1007/s00401-013-1126-5.

1891